

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.

**THIS PAGE BLANK (USPTO)**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

[illegible]

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Neutrokin $\alpha$

### *Field of the Invention*

The present invention relates to a novel cytokine expressed by neutrophils which has therefore been designated Neutrokin  $\alpha$  protein ("Neutrokin  $\alpha$ "). In particular, isolated nucleic acid molecules are provided encoding the Neutrokin  $\alpha$  protein. Neutrokin  $\alpha$  polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same.

### *Related Art*

Human tumor necrosis factors (TNF- $\alpha$ ) and (TNF- $\beta$ , or lymphotoxin) are related members of a broad class of polypeptide mediators, which includes the interferons, interleukins and growth factors, collectively called cytokines (Beutler, B. and Cerami, A., *Annu. Rev. Immunol.*, 7:625-655 (1989)). Sequence analysis of cytokine receptors has defined several subfamilies of membrane proteins (1) the Ig superfamily, (2) the hematopoietin (cytokine receptor superfamily and (3) the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor superfamily (for review of TNF superfamily see, Gruss and Dower, *Blood* 85(12):3378-3404 (1995) and Aggarwal and Natarajan, *Eur. Cytokine Netw.*, 7(2):93-124 (1996)). The TNF/NGF receptor superfamily contains at least 10 difference proteins. Gruss and Dower, *supra*. Ligands for these receptors have been identified and belong to at least two cytokine superfamilies. Gruss and Dower, *supra*.

Tumor necrosis factor (a mixture of TNF- $\alpha$  and TNF- $\beta$ ) was originally discovered as a result of its anti-tumor activity, however, now it is recognized as a pleiotropic cytokine capable of numerous biological activities including apoptosis of some transformed cell lines, mediation of cell activation and proliferation and also as playing important roles in immune regulation and inflammation.

2

To date, known members of the TNF-ligand superfamily include TNF- $\alpha$ , TNF- $\beta$  (lymphotoxin- $\alpha$ ), LT- $\beta$ , OX40L, Fas ligand, CD30L, CD27L, CD40L and 4-IBBL. The ligands of the TNF ligand superfamily are acidic, TNF-like molecules with approximately 20% sequence homology in the extracellular domains (range, 12%-36%) and exist mainly as membrane-bound forms with the biologically active form being a trimeric/multimeric complex. Soluble forms of the TNF ligand superfamily have only been identified so far for TNF, LT  $\beta$ , and Fas ligand (for a general review, see Gruss, H. and Dower, S.K., *Blood*, 85(12):3378-3404 (1995)), which is hereby incorporated by reference in its entirety. These proteins are involved in regulation of cell proliferation, activation, and differentiation, including control of cell survival or death by apoptosis or cytotoxicity (Armitage, R.J., *Curr. Opin. Immunol.* 6:407 (1994) and Smith, C.A., *Cell* 75:959 (1994)).

Tumor necrosis factor-alpha (TNF  $\alpha$ ; also termed cachectin; hereinafter "TNF") is secreted primarily by monocytes and macrophages in response to endotoxin or other stimuli as a soluble homotrimer of 17 kD protein subunits (Smith, R.A. *et al.*, *J. Biol. Chem.* 262:6951-6954 (1987)). A membrane-bound 26 kD precursor form of TNF has also been described (Kriegler, M. *et al.*, *Cell* 53:45-53 (1988)).

Accumulating evidence indicates that TNF is a regulatory cytokine with pleiotropic biological activities. These activities include: inhibition of lipoprotein lipase synthesis ("cachectin" activity) (Beutler, B. *et al.*, *Nature* 316:552 (1985)), activation of polymorphonuclear leukocytes (Klebanoff, S.J. *et al.*, *J. Immunol.* 136:4220 (1986); Perussia, B., *et al.*, *J. Immunol.* 138:765 (1987)), inhibition of cell growth or stimulation of cell growth (Vilcek, J. *et al.*, *J. Exp. Med.* 163:632 (1986); Sugarman, B. J. *et al.*, *Science* 230:943 (1985); Lachman, L.B. *et al.*, *J. Immunol.* 138:2913 (1987)), cytotoxic action on certain transformed cell types (Lachman, L.B. *et al.*, *supra*; Darzynkiewicz, Z. *et al.*, *Canc. Res.* 44:83 (1984)), antiviral activity (Kohase, M. *et al.*, *Cell* 45:659 (1986); Wong, G.H.W. *et al.*, *Nature* 323:819 (1986)), stimulation of bone

resorption (Bertolini, D.R. *et al.*, *Nature* 319:516 (1986); Saklatvala, J., *Nature* 322:547 (1986)), stimulation of collagenase and prostaglandin E2 production (Dayer, J.-M. *et al.*, *J. Exp. Med.* 162:2163 (1985)); and immunoregulatory actions, including activation of T cells (Yokota, S. *et al.*, *J. Immunol.* 140:531 (1988)), B cells (Kehrl, J.H. *et al.*, *J. Exp. Med.* 166:786 (1987)), monocytes (Philip, R. *et al.*, *Nature* 323:86 (1986)), thymocytes (Ranges, G.E. *et al.*, *J. Exp. Med.* 167:1472 (1988)), and stimulation of the cell-surface expression of major histocompatibility complex (MHC) class I and class II molecules (Collins, T. *et al.*, *Proc. Natl. Acad. Sci. USA* 83:446 (1986); Pujol-Borrel, R. *et al.*, *Nature* 326:304 (1987)).

TNF is noted for its pro-inflammatory actions which result in tissue injury, such as induction of procoagulant activity on vascular endothelial cells (Poher, J.S. *et al.*, *J. Immunol.* 136:1680 (1986)), increased adherence of neutrophils and lymphocytes (Poher, J.S. *et al.*, *J. Immunol.* 138:3319 (1987)), and stimulation of the release of platelet activating factor from macrophages, neutrophils and vascular endothelial cells (Camussi, G. *et al.*, *J. Exp. Med.* 166:1390 (1987)).

Recent evidence implicates TNF in the pathogenesis of many infections (Cerami, A. *et al.*, *Immunol. Today* 9:28 (1988)), immune disorders, neoplastic pathology, e.g., in cachexia accompanying some malignancies (Oloff, A. *et al.*, *Cell* 50:555 (1987)), and in autoimmune pathologies and graft-versus host pathology (Piguet, P.-F. *et al.*, *J. Exp. Med.* 166:1280 (1987)). The association of TNF with cancer and infectious pathologies is often related to the host's catabolic state. A major problem in cancer patients is weight loss, usually associated with anorexia. The extensive wasting which results is known as "cachexia" (Kern, K. A. *et al.*, *J. Parent. Enter. Nutr.* 12:286-298 (1988)). Cachexia includes progressive weight loss, anorexia, and persistent erosion of body mass in response to a malignant growth. The cachectic state is thus associated with significant morbidity and is responsible for the majority of cancer mortality. A number of studies have suggested that TNF is an

4

important mediator of the cachexia in cancer, infectious pathology, and in other catabolic states.

TNF is thought to play a central role in the pathophysiological consequences of Gram-negative sepsis and endotoxic shock (Michie, H.R. *et al.*, *Br. J. Surg.* 76:670-671 (1989); Debets, J. M. H. *et al.*, *Second Vienna Shock Forum*, p.463-466 (1989); Simpson, S. Q. *et al.*, *Crit. Care Clin.* 5:27-47 (1989)), including fever, malaise, anorexia, and cachexia. Endotoxin is a potent monocyte/macrophage activator which stimulates production and secretion of TNF (Kornbluth, S.K. *et al.*, *J. Immunol.* 137:2585-2591 (1986)) and other cytokines. Because TNF could mimic many biological effects of endotoxin, it was concluded to be a central mediator responsible for the clinical manifestations of endotoxin-related illness. TNF and other monocyte-derived cytokines mediate the metabolic and neurohormonal responses to endotoxin (Michie, H.R. *et al.*, *N. Eng. J. Med.* 318:1481-1486 (1988)). Endotoxin administration to human volunteers produces acute illness with flu-like symptoms including fever, tachycardia, increased metabolic rate and stress hormone release (Revhaug, A. *et al.*, *Arch. Surg.* 123:162-170 (1988)). Elevated levels of circulating TNF have also been found in patients suffering from Gram-negative sepsis (Waage, A. *et al.*, *Lancet* 1:355-357 (1987); Hammerle, A.F. *et al.*, *Second Vienna Shock Forum* p. 715-718 (1989); Debets, J. M. H. *et al.*, *Crit. Care Med.* 17:489-497 (1989); Calandra, T. *et al.*, *J. Infect. Dis.* 161:982-987 (1990)).

Passive immunotherapy directed at neutralizing TNF may have a beneficial effect in Gram-negative sepsis and endotoxemia, based on the increased TNF production and elevated TNF levels in these pathology states, as discussed above. Antibodies to a "modulator" material which was characterized as cachectin (later found to be identical to TNF) were disclosed by Cerami *et al.* (EPO Patent Publication 0,212,489, March 4, 1987). Such antibodies were said to be useful in diagnostic immunoassays and in therapy of shock in bacterial infections. Rubin *et al.* (EPO Patent Publication 0,218,868,



April 22, 1987) disclosed monoclonal antibodies to human TNF, the hybridomas secreting such antibodies, methods of producing such antibodies, and the use of such antibodies in immunoassay of TNF. Yone *et al.* (EPO Patent Publication 0,288,088, October 26, 1988) disclosed anti-TNF antibodies, including mAbs, and their utility in immunoassay diagnosis of pathologies, in particular Kawasaki's pathology and bacterial infection. The body fluids of patients with Kawasaki's pathology (infantile acute febrile mucocutaneous lymph node syndrome; Kawasaki, T., *Allergy* 16:178 (1967); Kawasaki, T., *Shonica (Pediatrics)* 26:935 (1985)) were said to contain elevated TNF levels which were related to progress of the pathology (Yone *et al.*, *supra*).

Other investigators have described mAbs specific for recombinant human TNF which had neutralizing activity *in vitro* (Liang, C-M. *et al. Biochem. Biophys. Res. Comm.* 137:847-854 (1986); Meager, A. *et al., Hybridoma* 6:305-311 (1987); Fendly *et al., Hybridoma* 6:359-369 (1987); Bringman, T S *et al., Hybridoma* 6:489-507 (1987); Hirai, M. *et al., J. Immunol. Meth.* 96:57-62 (1987); Moller, A. *et al. (Cytokine* 2:162-169 (1990)). Some of these mAbs were used to map epitopes of human TNF and develop enzyme immunoassays (Fendly *et al., supra*; Hirai *et al., supra*; Moller *et al., supra*) and to assist in the purification of recombinant TNF (Bringman *et al., supra*). However, these studies do not provide a basis for producing TNF neutralizing antibodies that can be used for *in vivo* diagnostic or therapeutic uses in humans, due to immunogenicity, lack of specificity and/or pharmaceutical suitability.

Neutralizing antisera or mAbs to TNF have been shown in mammals other than man to abrogate adverse physiological changes and prevent death after lethal challenge in experimental endotoxemia and bacteremia. This effect has been demonstrated, e.g., in rodent lethality assays and in primate pathology model systems (Mathison, J.C. *et al., J. Clin. Invest.* 81:1925-1937 (1988); Beutler, B. *et al., Science* 229:869-871 (1985); Tracey, K. J. *et al.*,

6

*Nature* 330:662-664 (1987); Shimamoto, Y. *et al.*, *Immunol. Lett.* 17:311-318 (1988); Silva, A. T. *et al.*, *J. Infect. Dis.* 162:421-427 (1990); Opal, S. M. *et al.*, *J. Infect. Dis.* 161:1148-1152 (1990); Hinshaw, L.B. *et al.*, *Circ. Shock* 30:279-292 (1990)).

5 To date, experience with anti-TNF mAb therapy in humans has been limited but shows beneficial therapeutic results, *e.g.*, in arthritis and sepsis. See, *e.g.*, Elliott, M. J. *et al.*, *Baillieres Clin. Rheumatol.* 9:633-52 (1995); Feldmann M, *et al.*, *Ann. N. Y. Acad. Sci. USA* 766:272-8 (1995); van der Poll, T. *et al.*, *Shock* 3:1-12 (1995); Wherry *et al.*, *Crit. Care. Med.* 21:S436-40  
10 (1993); Tracey K. J., *et al.*, *Crit. Care Med.* 21:S415-22 (1993).

Mammalian development is dependent on both the proliferation and differentiation of cells as well as programmed cell death which occurs through apoptosis (Walker, *et al.*, *Methods Achiev. Exp. Pathol.* 13:18 (1988). Apoptosis plays a critical role in the destruction of immune thymocytes that  
15 recognize self antigens. Failure of this normal elimination process may play a role in autoimmune diseases (Gammon *et al.*, *Immunology Today* 12:193 (1991)).

Itoh *et al.* (*Cell* 66:233 (1991)) described a cell surface antigen, Fas/CD23 that mediates apoptosis and is involved in clonal deletion of T-cells.  
20 Fas is expressed in activated T-cells, B-cells, neutrophils and in thymus, liver, heart and lung and ovary in adult mice (Watanabe-Fukunaga *et al.*, *J. Immunol.* 148:1274 (1992)) in addition to activated T-cells, B-cells, neutrophils. In experiments where a monoclonal Ab is cross-linked to Fas, apoptosis is induced (Yonehara *et al.*, *J. Exp. Med.* 169:1747 (1989); Trauth *et al.*, *Science*  
25 245:301 (1989)). In addition, there is an example where binding of a monoclonal Ab to Fas is stimulatory to T-cells under certain conditions (Alderson *et al.*, *J. Exp. Med.* 178:2231 (1993)).

Fas antigen is a cell surface protein of relative MW of 45 Kd. Both human and murine genes for Fas have been cloned by Watanabe-Fukunaga *et al.*, (*J. Immunol.* 148:1274 (1992)) and Itoh *et al.* (*Cell* 66:233 (1991)). The  
30

7  
proteins encoded by these genes are both transmembrane proteins with structural homology to the Nerve Growth Factor/Tumor Necrosis Factor receptor superfamily, which includes two TNF receptors, the low affinity Nerve Growth Factor receptor and CD40, CD27, CD30, and OX40.

5        Recently the Fas ligand has been described (Suda *et al.*, *Cell* 75:1169 (1993)). The amino acid sequence indicates that Fas ligand is a type II transmembrane protein belonging to the TNF family. Thus, the Fas ligand polypeptide comprises three main domains: a short intracellular domain at the amino terminal end and a longer extracellular domain at the carboxy terminal  
10       end, connected by a hydrophobic transmembrane domain. Fas ligand is expressed in splenocytes and thymocytes, consistent with T-cell mediated cytotoxicity. The purified Fas ligand has a MW of 40 kD.

      Recently, it has been demonstrated that Fas/Fas ligand interactions are required for apoptosis following the activation of T-cells (Ju *et al.*, *Nature*  
15       373:444 (1995); Brunner *et al.*, *Nature* 373:441 (1995)). Activation of T-cells induces both proteins on the cell surface. Subsequent interaction between the ligand and receptor results in apoptosis of the cells. This supports the possible regulatory role for apoptosis induced by Fas/Fas ligand interaction during normal immune responses.

20       Accordingly, there is a need to provide cytokines similar to TNF that are involved in pathological conditions. Such novel cytokines could be used to make novel antibodies or other antagonists that bind these TNF-like cytokines for therapy of disorders related to TNF-like cytokines.

### *Summary of the Invention*

25       The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a cytokine that is structurally similar to TNF and related cytokines and is believed to have similar biological effects and activities. This cytokine is named Neutrokin  $\alpha$  and the invention includes Neutrokin  $\alpha$  polypeptides having at least a portion of the amino acid  
30       sequence in FIG. 1 (SEQ ID NO:2) or amino acid sequence encoded by the

cDNA clone deposited in a bacterial host as ATCC Deposit on October 22, 1996. The nucleotide sequence determined by sequencing the deposited Neutrokin  $\alpha$  clone, which is shown in Figure 1 (SEQ ID NO:1), contains an open reading frame encoding a complete polypeptide of 285 amino acid residues including an N-terminal methionine, a predicted intracellular domain of about 46 amino acid residues, a predicted transmembrane domain of about 26 amino acids, a predicted extracellular domain of about 213 amino acids, and a deduced molecular weight for the complete protein of about 31 kDa. As for other type II transmembrane proteins, soluble forms of Neutrokin  $\alpha$  include all or a portion of the extracellular domain cleaved from the transmembrane domain and a polypeptide comprising the complete Neutrokin  $\alpha$  polypeptide lacking the transmembrane domain, i.e., the extracellular domain linked to the intracellular domain.

Thus, one aspect of the invention provides an isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding a full-length Neutrokin  $\alpha$  polypeptide having the complete amino acid sequence in Figure 1 (SEQ ID NO:2) or as encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996; (b) a nucleotide sequence encoding the predicted extracellular domain of the Neutrokin  $\alpha$  polypeptide having the amino acid sequence at positions 73 to 285 in Figure 1 (SEQ ID NO:2) or as encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996; (c) a nucleotide sequence encoding a polypeptide comprising the Neutrokin  $\alpha$  intracellular domain (amino acid residues from about 1 to about 46 in FIG. 1 (SEQ ID NO:2)) or as encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996; (d) a nucleotide sequence encoding a polypeptide comprising the Neutrokin  $\alpha$  transmembrane domain (amino acid residues from about 47 to about 72 in FIG. 1 (SEQ ID NO:2) or as encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996; (e) a nucleotide sequence encoding a soluble Neutrokin  $\alpha$  polypeptide having the

extracellular and intracellular domains but lacking the transmembrane domain;  
and (f) a nucleotide sequence complementary to any of the nucleotide  
sequences in (a), (b), (c), (d) or (e) above.

Further embodiments of the invention include isolated nucleic acid  
5 molecules that comprise a polynucleotide having a nucleotide sequence at least  
90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99%  
identical, to any of the nucleotide sequences in (a), (b), (c), (d), (e) or (f) above,  
or a polynucleotide which hybridizes under stringent hybridization conditions  
to a polynucleotide in (a), (b), (c), (d), (e) or (f) above. This polynucleotide  
10 which hybridizes does not hybridize under stringent hybridization conditions  
to a polynucleotide having a nucleotide sequence consisting of only A residues  
or of only T residues. An additional nucleic acid embodiment of the invention  
relates to an isolated nucleic acid molecule comprising a polynucleotide which  
encodes the amino acid sequence of an epitope-bearing portion of a Neutrokin  $\alpha$   
15  $\alpha$  polypeptide having an amino acid sequence in (a), (b), (c), (d) or (e) above.

The present invention also relates to recombinant vectors, which  
include the isolated nucleic acid molecules of the present invention, and to host  
cells containing the recombinant vectors, as well as to methods of making such  
vectors and host cells and for using them for production of Neutrokin  $\alpha$   
20 polypeptides or peptides by recombinant techniques.

The invention further provides an isolated Neutrokin  $\alpha$  polypeptide  
comprising an amino acid sequence selected from the group consisting of: (a)  
the amino acid sequence of the full-length Neutrokin  $\alpha$  polypeptide having  
the complete amino acid sequence shown in Figure 1 (SEQ ID NO:2) or as  
25 encoded by the cDNA clone contained in the ATCC Deposit of October 22,  
1996; (b) the amino acid sequence of the predicted extracellular domain of the  
Neutrokin  $\alpha$  polypeptide having the amino acid sequence at positions 73 to  
285 in Figure 1 (SEQ ID NO:2) or as encoded by the cDNA clone contained in  
the ATCC Deposit of October 22, 1996; (c) the amino acid sequence of the  
30 Neutrokin  $\alpha$  intracellular domain (amino acid residues from about 1 to about

46 in FIG. 1 (SEQ ID NO:2)) or as encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996; (d) the amino acid sequence of the Neutrokin  $\alpha$  transmembrane domain (amino acid residues from about 47 to about 72 in FIG. 1 (SEQ ID NO:2) or as encoded by the cDNA clone  
5 contained in the ATCC Deposit of October 22, 1996; and (e) the amino acid sequence of the soluble Neutrokin  $\alpha$  polypeptide having the extracellular and intracellular domains but lacking the transmembrane domain, wherein each of these domains is defined above.

The polypeptides of the present invention also include polypeptides  
10 having an amino acid sequence with at least 90% similarity, and more preferably at least 95% similarity to those described in (a), (b), (c), (d) or (e) above, as well as polypeptides having an amino acid sequence at least 80% identical, more preferably at least 90% identical, and still more preferably 95%, 96%, 97%, 98% or 99% identical to those above.

15 An additional embodiment of this aspect of the invention relates to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a Neutrokin  $\alpha$  polypeptide having an amino acid sequence described in (a), (b), (c), (d) or (e) above. Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a Neutrokin  
20  $\alpha$  polypeptide of the invention include portions of such polypeptides with at least six or seven, preferably at least nine, and more preferably at least about 30 amino acids to about 50 amino acids, although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a polypeptide of the invention described above also are included in the  
25 invention. In another embodiment, the invention provides an isolated antibody that binds specifically to an polypeptide having an amino acid sequence described in (a), (b), (c), (d) or (e) above.

The invention further provides methods for isolating antibodies that bind specifically to an Neutrokin  $\alpha$  polypeptide having an amino acid

sequence as described herein. Such antibodies are useful diagnostically or therapeutically as described below.

The invention also provides for pharmaceutical compositions comprising soluble Neutrokin  $\alpha$  polypeptides, particularly human  
5 Neutrokin  $\alpha$  polypeptides, which may be employed, for instance, to treat tumor and tumor metastasis, infections by bacteria, viruses and other parasites, immunodeficiencies, inflammatory diseases, lymphadenopathy, autoimmune diseases, graft versus host disease and to stimulate peripheral tolerance, destroy some transformed cell lines, mediate cell activation and  
10 proliferation, and are functionally linked as primary mediators of immune regulation and inflammatory responses.

The invention further provides compositions comprising an Neutrokin  $\alpha$  polynucleotide or an Neutrokin  $\alpha$  polypeptide for administration to cells *in vitro*, to cells *ex vivo* and to cells *in vivo*, or to a multicellular organism. In  
15 certain particularly preferred embodiments of this aspect of the invention, the compositions comprise an Neutrokin  $\alpha$  polynucleotide for expression of an Neutrokin  $\alpha$  polypeptide in a host organism for treatment of disease. Particularly preferred in this regard is expression in a human patient for treatment of a dysfunction associated with aberrant endogenous activity of an  
20 Neutrokin  $\alpha$  gene.

The present invention also provides a screening method for identifying compounds capable of enhancing or inhibiting a cellular response induced by Neutrokin  $\alpha$  which involves contacting cells which express Neutrokin  $\alpha$  with the candidate compound, assaying a cellular response, and comparing the  
25 cellular response to a standard cellular response, the standard being assayed when contact is made in absence of the candidate compound; whereby, an increased cellular response over the standard indicates that the compound is an agonist and a decreased cellular response over the standard indicates that the compound is an antagonist.

In another aspect, a method for identifying Neutrokin  $\alpha$  receptors is provided, as well as a screening assay for agonists and antagonists using such receptors. This assay involves determining the effect a candidate compound has on Neutrokin  $\alpha$  binding to the Neutrokin  $\alpha$  receptor. In particular, the method involves contacting a Neutrokin  $\alpha$  receptor with an Neutrokin  $\alpha$  polypeptide and a candidate compound and determining whether Neutrokin  $\alpha$  polypeptide binding to the Neutrokin  $\alpha$  receptor is increased or decreased due to the presence of the candidate compound. The antagonists may be employed to prevent septic shock, inflammation, cerebral malaria, activation of the HIV virus, graft-host rejection, bone resorption, rheumatoid arthritis and cachexia (wasting or malnutrition)

The present inventors have discovered that Neutrokin  $\alpha$  is expressed not only in neutrophils, but also in kidney, lung, peripheral leukocyte, bone marrow, T cell lymphoma, B cell lymphoma, activated T cells, stomach cancer, smooth muscle, macrophages, cord blood tissue. For a number of disorders of these tissues and cells, such as tumor and tumor metastasis, infection of bacteria, viruses and other parasites, immunodeficiencies, septic shock, inflammation, cerebral malaria, activation of the HIV virus, graft-host rejection, bone resorption, rheumatoid arthritis and cachexia (wasting or malnutrition, it is believed that significantly higher or lower levels of Neutrokin  $\alpha$  gene expression can be detected in certain tissues (e.g., bone marrow) or bodily fluids (e.g., serum, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a "standard" Neutrokin  $\alpha$  gene expression level, i.e., the Neutrokin  $\alpha$  expression level in tissue or bodily fluids from an individual not having the disorder. Thus, the invention provides a diagnostic method useful during diagnosis of a disorder, which involves: (a) assaying Neutrokin  $\alpha$  gene expression level in cells or body fluid of an individual; (b) comparing the Neutrokin  $\alpha$  gene expression level with a standard Neutrokin  $\alpha$  gene expression level, whereby an increase or decrease



in the assayed Neutrokin  $\alpha$  gene expression level compared to the standard expression level is indicative of a disorder.

An additional aspect of the invention is related to a method for treating an individual in need of an increased level of Neutrokin  $\alpha$  activity in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an isolated Neutrokin  $\alpha$  polypeptide of the invention or an agonist thereof.

A still further aspect of the invention is related to a method for treating an individual in need of a decreased level of Neutrokin  $\alpha$  activity in the body comprising, administering to such an individual a composition comprising a therapeutically effective amount of an Neutrokin  $\alpha$  antagonist. Preferred antagonists for use in the present invention are Neutrokin  $\alpha$  -specific antibodies.

### *Brief Description of the Figures*

FIG. 1 shows the nucleotide (SEQ ID NO:1) and deduced amino acid (SEQ ID NO:2) sequences of the Neutrokin  $\alpha$  protein. Amino acids 1 to 46 represent the intracellular domain, amino acids 47 to 72 the transmembrane domain (the underlined sequence), and amino acids 73 to 285, the extracellular domain (the remaining sequence).

Figure 2 shows the regions of identity between the amino acid sequences of the Neutrokin  $\alpha$  protein and TNF- $\alpha$  (SEQ ID NO:3), TNF- $\beta$  (lymphotoxin) (SEQ ID NO:4) and FAS ligand (SEQ ID NO:5), determined by the "Megalign" routine which is part of the computer program called "DNASTar".

Figure 3 shows an analysis of the Neutrokin  $\alpha$  amino acid sequence. Alpha, beta, turn and coil regions; hydrophilicity and hydrophobicity; amphipathic regions; flexible regions; antigenic index and surface probability are shown. In the "Antigenic Index - Jameson-Wolf" graph, the indicate

location of the highly antigenic regions of the Neutrokin  $\alpha$  protein, i.e., regions from which epitope-bearing peptides of the invention may be obtained.

Figure 4 shows the alignment of the Neutrokin  $\alpha$  nucleotide sequence determined from the human cDNA deposited in the ATCC Deposit of October 22, 1996 with related human cDNA clones of the invention which have been designated HSOAD55R (SEQ ID NO:7), HSLAH84R (SEQ ID NO:8) and HLTBM08R (SEQ ID NO:9).

### *Detailed Description*

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding Neutrokin  $\alpha$  polypeptide having the amino acid sequence shown in Figure 1 (SEQ ID NO:2), which was determined by sequencing a cloned cDNA Neutrokin  $\alpha$ . The nucleotide sequence shown in Figure 1 (SEQ ID NO:1) was obtained by sequencing the HNEDU15 clone, which was deposited on October 22, 1996 at the American Type Culture Collection, 12301 Park Lawn Drive, Rockville, Maryland. The deposited clone is contained in the pBluescript SK(-) plasmid (Stratagene, La Jolla, CA).

The Neutrokin  $\alpha$  protein of the present invention shares sequence homology with the translation product of the human mRNAs for TNF- $\alpha$ , TNF- $\beta$  and Fas ligand (Figure 2). As noted above, TNF- $\alpha$  is thought to be an important cytokine that plays a role in cytotoxicity, necrosis, apoptosis, costimulation, proliferation, lymph node formation, immunoglobulin class switch, differentiation, antiviral activity, regulation of adhesion molecules and other cytokines and growth factors.

### *Nucleic Acid Molecules*

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc., Foster City, CA), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence

determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

By "nucleotide sequence" of a nucleic acid molecule or polynucleotide is intended, for a DNA molecule or polynucleotide, a sequence of deoxyribonucleotides, and for an RNA molecule or polynucleotide, the corresponding sequence of ribonucleotides (A, G, C and U), where each thymidine deoxyribonucleotide (T) in the specified deoxyribonucleotide sequence is replaced by the ribonucleotide uridine (U).

Using the information provided herein, such as the nucleotide sequence in Figure 1, a nucleic acid molecule of the present invention encoding a Neutrokin  $\alpha$  polypeptide may be obtained using standard cloning and screening procedures, such as those for cloning cDNAs using mRNA as starting material. Illustrative of the invention, the nucleic acid molecule described in Figure 1 (SEQ ID NO:1) was discovered in a cDNA library derived from neutrophils. Expressed sequence tags corresponding to a portion of the Neutrokin  $\alpha$  cDNA were also found in neutrophil

The Neutrokin  $\alpha$  gene contains an open reading frame encoding a protein of about 285 amino acid residues, an intracellular domain of about 46

amino acids (amino acid residues from about 1 to about 46 in Figure 1 (SEQ ID NO:2)), a transmembrane domain of about 26 amino acids (amino acid residues from about 47 to about 72 in FIG. 1 (SEQ ID NO:2)), an extracellular domain of about 213 amino acids (amino acid residues from about 73 to about 285 in Figure 1 (SEQ ID NO:2)); and a deduced molecular weight of about 31 kDa. The Neutrokin  $\alpha$  protein shown in Figure 1 (SEQ ID NO: 2) is about 20% similar and about 10 % identical to human TNF- $\alpha$  which can be accessed on GenBank as Accession No. 339764.

As one of ordinary skill would appreciate, due to the possibilities of sequencing errors discussed above, the actual complete Neutrokin  $\alpha$  polypeptide encoded by the deposited cDNA, which comprises about 285 amino acids, may be somewhat shorter. In particular, the determined Neutrokin  $\alpha$  coding sequence contains a second methionine codon which may serve as an alternative start codon for translation of the open reading frame, at nucleotide positions 210-213 in Figure 1 (SEQ ID NO:1). More generally, the actual open reading frame may be anywhere in the range of  $\pm 20$  amino acids, more likely in the range of  $\pm 10$  amino acids, of that predicted from either the first or second methionine codon from the N-terminus shown in Figure 1 (SEQ ID NO:1). It will further be appreciated that, depending on the analytical criteria used for identifying various functional domains, the exact "address" of the extracellular, intracellular and transmembrane domains of the Neutrokin  $\alpha$  polypeptide may differ slightly. For example, the exact location of the Neutrokin  $\alpha$  extracellular domain in Figure 1 (SEQ ID NO:2) may vary slightly (e.g., the address may "shift" by about 1 to about 20 residues, more likely about 1 to about 5 residues) depending on the criteria used to define the domain. In this case, the ends of the transmembrane domain and the beginning of the extracellular domain were predicted on the basis of the identification of the hydrophobic amino acid sequence in the above indicated positions, as shown in Figure 3. In any event, as discussed further below, the invention further provides polypeptides having various residues deleted from the

N-terminus of the complete polypeptide, including polypeptides lacking one or more amino acids from the N-terminus of the extracellular domain described herein, which constitute soluble forms of the extracellular domain of the Neutrokin  $\alpha$  protein.

5           As indicated, nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the  
10       sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

          By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered  
15       isolated for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. Isolated nucleic  
20       acid molecules according to the present invention further include such molecules produced synthetically.

          Isolated nucleic acid molecules of the present invention include DNA molecules comprising an open reading frame (ORF) with an initiation codon at positions 147-149 of the nucleotide sequence shown in Figure 1 (SEQ ID  
25       NO:1). In addition, isolated nucleic acid molecules of the invention include DNA molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the Neutrokin  $\alpha$  protein. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate the  
30       degenerate variants described above. In another aspect, the invention provides

isolated nucleic acid molecules encoding the Neutrokin  $\alpha$  polypeptide having an amino acid sequence encoded by the cDNA contained in the plasmid deposited on October 22, 1996. Preferably, this nucleic acid molecule will comprise a sequence encoding the extracellular domain of the polypeptide encoded by the above-described deposited cDNA clone.

The invention further provides an isolated nucleic acid molecule having the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) or the nucleotide sequence of the Neutrokin  $\alpha$  cDNA contained in the above-described deposited clone, or a nucleic acid molecule having a sequence complementary to one of the above sequences. Such isolated molecules, particularly DNA molecules, are useful as probes for gene mapping, by *in situ* hybridization with chromosomes, and for detecting expression of the Neutrokin  $\alpha$  gene in human tissue, for instance, by Northern blot analysis.

The present invention is further directed to nucleic acid molecules encoding portions of the nucleotide sequences described herein as well as to fragments of the isolated nucleic acid molecules described herein. In particular, the invention provides a polynucleotide having a nucleotide sequence representing the portion of SEQ ID NO:1 which consists of positions 1-1001 of SEQ ID NO:1.

Further, the invention includes a polynucleotide comprising a sequence at least 95% identical to any portion of at least about 30 contiguous nucleotides, preferably at least about 50 nucleotides, of the sequence from nucleotide 1 to nucleotide 809 in Figure 1 (SEQ ID NO:1).

More generally, by a fragment of an isolated nucleic acid molecule having the nucleotide sequence of the deposited cDNA or the nucleotide sequence shown in Figure 1 (SEQ ID NO:1) is intended fragments at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably, at least about 40 nt in length which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments 50-300 nt in length are also useful according to the

present invention as are fragments corresponding to most, if not all, of the nucleotide sequence of the deposited cDNA or as shown in Figure 1 (SEQ ID NO:1). By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in Figure 1 (SEQ ID NO:1). Preferred nucleic acid fragments of the present invention include nucleic acid molecules encoding epitope-bearing portions of the Neutrokin  $\alpha$  polypeptide as identified in Figure 1 and described in more detail below.

In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a portion of the polynucleotide in a nucleic acid molecule of the invention described above, for instance, the cDNA clone contained in the ATCC Deposit of October 22, 1996. By "stringent hybridization conditions" is intended overnight incubation at 42° C in a solution comprising: 50% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20  $\mu$ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65° C.

By a polynucleotide which hybridizes to a "portion" of a polynucleotide is intended a polynucleotide (either DNA or RNA) hybridizing to at least about 15 nucleotides (nt), and more preferably at least about 20 nt, still more preferably at least about 30 nt, and even more preferably about 30-70 (e.g., 50) nt of the reference polynucleotide. These are useful as diagnostic probes and primers as discussed above and in more detail below.

By a portion of a polynucleotide of "at least 20 nt in length," for example, is intended 20 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (e.g., the deposited cDNA or the nucleotide sequence as shown in Figure 1 (SEQ ID NO:1)). Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3'

terminal poly(A) tract of the Neutrokin  $\alpha$  cDNA shown in Figure 1 (SEQ ID NO:1)), or to a complementary stretch of T (or U) residues, would not be included in a polynucleotide of the invention used to hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

As indicated, nucleic acid molecules of the present invention which encode a Neutrokin  $\alpha$  polypeptide may include, but are not limited to those encoding the amino acid sequence of the extracellular domain of the polypeptide, by itself; and the coding sequence for the extracellular domain of the polypeptide and additional sequences, such as those encoding the intracellular and transmembrane domain sequences, or a pre-, or pro- or prepro- protein sequence; the coding sequence of the extracellular domain of the polypeptide, with or without the aforementioned additional coding sequences.

Also encoded by nucleic acids of the invention are the above protein sequences together with additional, non-coding sequences, including for example, but not limited to introns and non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals, for example - ribosome binding and stability of mRNA; an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities.

Thus, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824



(1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. The "HA" tag is another peptide useful for purification which corresponds to an epitope derived from the influenza hemagglutinin protein, which has been described by Wilson et al., *Cell* 37: 767 (1984). As discussed below, other such fusion proteins include the Neutrokin  $\alpha$  fused to Fc at the N- or C-terminus.

#### ***Variant and Mutant Polynucleotides***

The present invention further relates to variants of the nucleic acid molecules of the present invention, which encode portions, analogs or derivatives of the Neutrokin  $\alpha$  protein. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. *Genes II*, Lewin, B., ed., John Wiley & Sons, New York (1985). Non-naturally occurring variants may be produced using art-known mutagenesis techniques.

Such variants include those produced by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding regions, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the Neutrokin  $\alpha$  protein or portions thereof. Also especially preferred in this regard are conservative substitutions.

Most highly preferred are nucleic acid molecules encoding the extracellular domain of the protein having the amino acid sequence shown in Figure 1 (SEQ ID NO:2) or the extracellular domain of the Neutrokin  $\alpha$  amino acid sequence encoded by the deposited cDNA clone. Further embodiments include an isolated nucleic acid molecule comprising a polynucleotide having a

22

nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical to a polynucleotide selected from the group consisting of: (a) a nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide having the complete amino acid sequence in Figure 1 (SEQ ID NO:2); (b) a nucleotide sequence encoding the predicted extracellular domain of the Neutrokin  $\alpha$  polypeptide having the amino acid sequence at positions 73-285 in Figure 1 (SEQ ID NO:2); (c) a nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in the ATCC of October 22, 1996; (d) a nucleotide sequence encoding the extracellular domain of the Neutrokin  $\alpha$  polypeptide having the amino acid sequence encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996; and (e) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c) or (d) above.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence encoding a Neutrokin  $\alpha$  polypeptide is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular nucleic acid molecule is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the nucleotide sequence shown in Figure 1 or to the nucleotides sequence of the deposited cDNA clone can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). Bestfit uses the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2:482-489 (1981), to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

The present application is directed to nucleic acid molecules at least 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1) or to the nucleic acid sequence of the deposited cDNA, irrespective of whether they encode a polypeptide having Neutrokin  $\alpha$  activity. This is because even where a particular nucleic acid molecule does not encode a polypeptide having Neutrokin  $\alpha$  activity, one of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having Neutrokin  $\alpha$  activity include, inter alia, (1) isolating the Neutrokin  $\alpha$  gene or allelic variants thereof in a cDNA library; (2) *in situ* hybridization (e.g., "FISH") to metaphase chromosomal spreads to provide precise chromosomal location of the Neutrokin  $\alpha$  gene, as described in Verma et al., *Human Chromosomes: A Manual of Basic Techniques*,

Pergamon Press, New York (1988); and Northern Blot analysis for detecting Neutrokin  $\alpha$  mRNA expression in specific tissues.

Preferred, however, are nucleic acid molecules having sequences at least 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1) or to the nucleic acid sequence of the deposited cDNA which do, in fact, encode a polypeptide having Neutrokin  $\alpha$  protein activity. By "a polypeptide having Neutrokin  $\alpha$  activity" is intended polypeptides exhibiting activity similar, but not necessarily identical, to an activity of the extracellular domain or of the full-length Neutrokin  $\alpha$  protein of the invention, as measured in a particular biological assay. For example, the Neutrokin  $\alpha$  protein of the present invention modulates cell proliferation, cytotoxicity and cell death. An *in vitro* cell proliferation, cytotoxicity and cell death assay for measuring the effect of a protein on certain cells can be performed by using reagents well known and commonly available in the art for detecting cell replication and/or death. For instance, numerous such assays for TNF-related protein activities are described in the various references in the Background section of this disclosure, above. Briefly, such an assay involves collecting human or animal (e.g., mouse) cells and mixing with (1) transfected host cell-supernatant containing Neutrokin  $\alpha$  protein (or a candidate polypeptide) or (2) nontransfected host cell-supernatant control, and measuring the effect on cell numbers or viability after incubation of certain period of time. Such cell proliferation modulation activities as can be measure in this type of assay are useful for treating tumor, tumor metastasis, infections, autoimmune diseases inflammation and other immune-related diseases.

Neutrokin  $\alpha$  modulates cell proliferation and differentiation in a dose-dependent manner in the above-described assay. Thus, "a polypeptide having Neutrokin  $\alpha$  protein activity" includes polypeptides that also exhibit any of the same cell modulatory (particularly immunomodulatory) activities in the above-described assays in a dose-dependent manner. Although the degree of

dose-dependent activity need not be identical to that of the Neutrokin  $\alpha$  protein, preferably, "a polypeptide having Neutrokin  $\alpha$  protein activity" will exhibit substantially similar dose-dependence in a given activity as compared to the Neutrokin  $\alpha$  protein (i.e., the candidate polypeptide will exhibit greater  
5 activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity relative to the reference Neutrokin  $\alpha$  protein).

Like other members of TNF family, Neutrokin  $\alpha$  exhibits activity on leukocytes including for example monocytes, lymphocytes and neutrophils. For this reason Neutrokin  $\alpha$  is active in directing the proliferation,  
10 differentiation and migration of these cell types. Such activity is useful for immune enhancement or suppression, myeloprotection, stem cell mobilization, acute and chronic inflammatory control and treatment of leukemia. Assays for measuring such activity are known in the art. For example, see Peters *et al.*, *Immun. Today* 17:273 (1996); Young *et al.*, *J. Exp. Med.* 182:1111 (1995);  
15 Caux *et al.*, *Nature* 390:258 (1992); and Santiago-Schwarz *et al.*, *Adv. Exp. Med. Biol.* 378:7 (1995)."]

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of the nucleic acid molecules having a sequence at least 90%, 95%, 96%, 97%, 98%, or 99%  
20 identical to the nucleic acid sequence of the deposited cDNA or the nucleic acid sequence shown in Figure 1 (SEQ ID NO:1) will encode a polypeptide "having Neutrokin  $\alpha$  protein activity." In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison  
25 assay. It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode a polypeptide having Neutrokin  $\alpha$  protein activity. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect protein function (e.g., replacing one

aliphatic amino acid with a second aliphatic amino acid), as further described below.

### *Vectors and Host Cells*

5 The present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of Neutrokin  $\alpha$  polypeptides or fragments thereof by recombinant techniques. The vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral  
10 vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells. The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an  
15 appropriate packaging cell line and then transduced into host cells.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp*, *phoA* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled  
20 artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the extracellular domain of the transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (UAA, UGA or UAG) appropriately  
25 positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in *E. coli* and other bacteria.

Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, 293 and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from QIAGEN, Inc., *supra*; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and p

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., *Basic Methods In Molecular Biology* (1986).

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein

comprises a heterologous region from immunoglobulin that is useful to stabilize and purify proteins. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262). On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5 has been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See, D. Bennett et al., *J. Molecular Recognition* 8:52-58 (1995) and K. Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995).

The Neutrokin  $\alpha$  protein can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition,



polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

### *Neutrokin $\alpha$ Polypeptides and Fragments*

5 The invention further provides an isolated Neutrokin  $\alpha$  polypeptide having the amino acid sequence encoded by the deposited cDNA, or the amino acid sequence in Figure 1 (SEQ ID NO:2), or a peptide or polypeptide comprising a portion of the above polypeptides.

### *Variant and Mutant Polypeptides*

10 To improve or alter the characteristics of Neutrokin  $\alpha$  polypeptides, protein engineering may be employed. Recombinant DNA technology known to those skilled in the art can be used to create novel mutant proteins or "muteins including single or multiple amino acid substitutions, deletions, additions or fusion proteins. Such modified polypeptides can show, e.g., enhanced activity or increased stability. In addition, they may be purified in  
15 higher yields and show better solubility than the corresponding natural polypeptide, at least under certain purification and storage conditions.

### *N-Terminal and C-Terminal Deletion Mutants*

For instance, for many proteins, including the extracellular domain or the mature form(s) of a secreted protein, it is known in the art that one or  
20 more amino acids may be deleted from the N-terminus or C-terminus without substantial loss of biological function. For instance, Ron et al., *J. Biol. Chem.*, 268:2984-2988 (1993) reported modified KGF proteins that had heparin binding activity even if 3, 8, or 27 amino-terminal amino acid residues were missing.

25 In the present case, since the protein of the invention is a member of the TNF polypeptide family, deletions of N-terminal amino acids up to the Gly (G) residue at position 191 in Figure 1 (SEQ ID NO:2) may retain some biological activity such as cytotoxicity to appropriate target cells.

Polypeptides having further N-terminal deletions including the Gly(G)residue would not be expected to retain such biological activities because it is known that this residue in TNF-related polypeptides is in the beginning of the conserved domain required for biological activities. However, even if deletion of one or more amino acids from the N-terminus of a protein results in modification of loss of one or more biological functions of the protein, other biological activities may still be retained. Thus, the ability of the shortened protein to induce and/or bind to antibodies which recognize the complete or extracellular domain of the protein generally will be retained when less than the majority of the residues of the complete or extracellular domain of the protein are removed from the N-terminus. Whether a particular polypeptide lacking N-terminal residues of a complete protein retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

Accordingly, the present invention further provides polypeptides having one or more residues from the amino terminus of the amino acid sequence of the Neutrokin  $\alpha$  shown in Figure 1( SEQ ID NO:2), up to the Gly191 residue from the amino terminus, and polynucleotides encoding such polypeptides. In particular, the present invention provides polypeptides having the amino acid sequence of residues n-190 of SEQ ID NO:2, where n is an integer in the range of 2-190 and 191 is the position of the first residue from the N-terminus of the complete Neutrokin  $\alpha$  polypeptide (shown in SEQ ID NO:2) believed to be required for activity of the Neutrokin  $\alpha$  protein. More in particular, the invention provides polynucleotides encoding polypeptides having the amino acid sequence of residues 2-285, 3-285, 4-285, 5-285, 6-285, 7-285, 8-285, 9-285, 10-285, 11-285, 12-285, 13-285, 14-285, 15-285, 16-285, 17-285, 18-285, 19-285, 20-285, 21-285, 22-285, 23-285, 24-285, 25-285, 26-285, 27-285, 28-285, 29-285, 30-285, 31-285, 32-285, 33-285, 34-285, 35-285, 36-285, 37-285, 38-285, 39-285, 40-285, 41-285, 42-285, 43-285, 44-285, 45-285, 46-285, 47-285, 48-285, 49-285, 50-285, 51-285, 52-285, 53-

285, 54-285, 55-285, 56-285, 57-285, 58-285, 59-285, 60-285, 61-285, 62-  
 285, 63-285, 64-285, 65-285, 66-285, 67-285, 68-285, 69-285, 70-285, 71-  
 285, 72-285, 73-285, 74-285, 75-285, 76-285, 77-285, 78-285, 79-285, 80-  
 285, , 81-285, 82-285, 83-285, 84-285, 85-285, 86-285, 87-285, 88-285, 89-  
 5 285, 90-285, 91-285, 92-285, 93-285, 94-285, 95-285, 96-285, 97-285, 98-  
 285, 99-285, 100-285, 101-285, 102-285, 103-285, 104-285, 105-285, 106-  
 285, 107-285, 108-285, 109-285, 110-285, 111-285, 112-285, 113-285, 114-  
 285, 115-285, 116-285, 117-285, 118-285, 119-285, 120-285, 121-285, 122-  
 285, 123-285, 124-285, 125-285, 126-285, 127-285, 128-285, 129-285, 130-  
 10 285, 131-285, 132-285, 133-285, 134-285, 135-285, 136-285, 137-285, 138-  
 285, 139-285, 140-285, 141-285, 142-285, 143-285, 144-285, 145-285, 146-  
 285, 147-285, 148-285, 149-285, 150-285, 151-285, 152-285, 153-285, 154-  
 285, 155-285, 156-285, 157-285, 158-285, 159-285, 160-285, 161-285, 162-  
 285, 163-285, 164-285, 165-285, 166-285, 167-285, 168-285, 169-285, 170-  
 15 285, 171-285, 172-285, 173-285, 174-285, 175-285, 176-285, 177-285, 178-  
 285, 179-285, 180-285, 181-285, 182-285, 183-285, 184-285, 185-285, 186-  
 285, 187-285, 188-285, 189-285, 190-285, of SEQ ID NO:2. Polynucleotides  
 encoding these polypeptides also are provided.

Similarly, many examples of biologically functional C-terminal deletion  
 20 muteins are known. For instance, Interferon gamma shows up to ten times  
 higher activities by deleting 8-10 amino acid residues from the carboxy  
 terminus of the protein (Döbeli et al., *J. Biotechnology* 7:199-216 (1988).  
 Since the present protein is a member of the TNF polypeptide family,  
 deletions of C-terminal amino acids up to the Leu at position 284 are expected  
 25 to retain most if not all biological activity such as receptor binding and  
 modulation of cell replication. Polypeptides having deletions of up to about  
 10 additional C-terminal residues (i.e., up to the Gly residue at position 273)  
 also may retain some activity such as receptor binding, although such  
 polypeptides would lack a portion of the conserved TNF domain beginning at  
 30 about Leu284. However, even if deletion of one or more amino acids from the

C-terminus of a protein results in modification or loss of one or more biological functions of the protein, other biological activities may still be retained. Thus, the ability of the shortened protein to induce and/or bind to antibodies which recognize the complete or mature protein generally will be retained when less than the majority of the residues of the complete or mature protein are removed from the C-terminus. Whether a particular polypeptide lacking C-terminal residues of a complete protein retains such immunologic activities can readily be determined by routine methods described herein and otherwise known in the art.

Accordingly, the present invention further provides polypeptides having one or more residues from the carboxy terminus of the amino acid sequence of the Neutrokin  $\alpha$  shown in Figure 1 (SEQ ID NO:2), up to the Gly274 residue from the carboxy terminus, and polynucleotides encoding such polypeptides. In particular, the present invention provides polypeptides having the amino acid sequence of residues 1-m of the amino acid sequence in SEQ ID NO:2, where m is any integer in the range of 274 to 284. More in particular, the invention provides polynucleotides encoding polypeptides having the amino acid sequence of residues 1-274, 1-275, 1-276, 1-277, 1-278, 1-279, 1-280, 1-281, 1-282, 1-283 and 1-284 of SEQ ID NO:2.

Polynucleotides encoding these polypeptides also are provided.

Also provided are polypeptides having one or more amino acids deleted from both the amino and the carboxyl termini, which may be described generally as having residues n-m of SEQ ID NO:2, where n and m are integers as described above. Also included are a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Neutrokin  $\alpha$  amino acid sequence encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996 where this portion excludes from 1 to 190 amino acids from the amino terminus or from 1 to 11 amino acids from the C-terminus of the complete amino acid sequence (or any combination of these N-terminal and C-terminal deletions) encoded by the cDNA clone in the deposited clone.

Polynucleotides encoding all of the above deletion polypeptides also are provided.

#### *Other Mutants*

In addition to terminal deletion forms of the protein discussed above, it will be recognized by one of ordinary skill in the art that some amino acid sequences of the Neutrokin  $\alpha$  polypeptide can be varied without significant effect of the structure or function of the protein. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the protein which determine activity.

Thus, the invention further includes variations of the Neutrokin  $\alpha$  polypeptide which show substantial Neutrokin  $\alpha$  polypeptide activity or which include regions of Neutrokin  $\alpha$  protein such as the protein portions discussed below. Such mutants include deletions, insertions, inversions, repeats, and type substitutions selected according to general rules known in the art so as to have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J. U. et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," *Science* 247:1306-1310 (1990), wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selections or screens to identify sequences that maintain functionality.

As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally

conserved. Other such phenotypically silent substitutions are described in Bowie, J. U. *et al.*, *supra*, and the references cited therein. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe, Tyr.

Thus, the fragment, derivative or analog of the polypeptide of Figure 1 (SEQ ID NO:2), or that encoded by the deposited cDNA, may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the extracellular domain of the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the extracellular domain of the polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the extracellular domain of the polypeptide or a proprotein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein

Thus, the **Neutrokin**  $\alpha$  of the present invention may include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation. As indicated, changes are preferably of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein (see Table 1).

TABLE 1. Conservative Amino Acid Substitutions:

Aromatic	Phenylalanine Tryptophan Tyrosine
Hydrophobic	Leucine Isoleucine Valine
Polar	Glutamine Asparagine
Basic	Arginine Lysine Histidine
Acidic	Aspartic Acid Glutamic Acid
Small	Alanine Serine Threonine Methionine Glycine

Amino acids in the Neutrokin  $\alpha$  protein of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, *Science* 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as receptor binding or *in vitro* or *in vitro* proliferative activity.

Of special interest are substitutions of charged amino acids with other charged or neutral amino acids which may produce proteins with highly desirable improved characteristics, such as less aggregation. Aggregation may not only reduce activity but also be problematic when preparing pharmaceutical formulations, because aggregates can be immunogenic (Pinckard *et al.*, *Clin. Exp. Immunol.* 2:331-340 (1967); Robbins *et al.*, *Diabetes* 36: 838-

845 (1987); Cleland *et al.*, *Crit. Rev. Therapeutic Drug Carrier Systems* 10:307-377 (1993).

Replacement of amino acids can also change the selectivity of the binding of a ligand to cell surface receptors. For example, Ostade *et al.*, *Nature* 361:266-268 (1993) describes certain mutations resulting in selective binding of TNF- $\alpha$  to only one of the two known types of TNF receptors. Since Neutrokin  $\alpha$  is a member of the TNF polypeptide family, mutations similar to those in TNF- $\alpha$  are likely to have similar effects in Neutrokin  $\alpha$ .

Sites that are critical for ligand-receptor binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992) and de Vos *et al.* *Science* 255:306-312 (1992)). Since Neutrokin  $\alpha$  is a member of the TNF-related protein family, to modulate rather than completely eliminate biological activities of Neutrokin  $\alpha$ , preferably mutations are made in sequences encoding amino acids in the TNF conserved domain, i.e., in positions 191-284 of Figure 1 (SEQ ID NO:2), more preferably in residues within this region which are not conserved in all members of the TGF family. By making a specific mutation in Neutrokin  $\alpha$  in the position where such a conserved amino acid is typically found in related TNFs, Neutrokin  $\alpha$  will act as an antagonist, thus possessing angiogenic activity. Accordingly, polypeptides of the present invention include Neutrokin  $\alpha$  mutants. Such Neutrokin  $\alpha$  mutants are comprised of the full-length or preferably the extracellular domain of the Neutrokin  $\alpha$  amino acid sequence shown in Figure 1 (SEQ ID NO:2). Also forming part of the present invention are isolated polynucleotides comprising nucleic acid sequences which encode the above Neutrokin  $\alpha$  mutants.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of the Neutrokin  $\alpha$  polypeptide can be substantially



purified by the one-step method described in Smith and Johnson, *Gene* 67:31-40 (1988).

The polypeptides of the present invention include the complete polypeptide encoded by the deposited cDNA including the intracellular, transmembrane and extracellular domains of the polypeptide encoded by the deposited cDNA, the extracellular domain minus the intracellular and transmembrane domains of the protein, the complete polypeptide of Figure 1 (SEQ ID NO:2), the extracellular domain of Figure 1 (SEQ ID NO:2) minus the intracellular and transmembrane domains, as well as polypeptides which have at least 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above.

Further polypeptides of the present invention include polypeptides at least 80% identical, more preferably at least 90% or 95% identical, still more preferably at least 96%, 97%, 98% or 99% identical to the polypeptide encoded by the deposited cDNA or to the polypeptide of Figure 1 (SEQ ID NO:2), and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.

By "% similarity" for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) and the default settings for determining similarity. Bestfit uses the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics 2:482-489, 1981) to find the best segment of similarity between two sequences.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a Neutrokin  $\alpha$  polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the

reference amino acid of the Neutrokin  $\alpha$  polypeptide. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, the amino acid sequence shown in Figure 1 (SEQ ID NO:2) or to the amino acid sequence encoded by deposited cDNA clone can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

The polypeptide of the present invention could be used as a molecular weight marker on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art.

As described in detail below, the polypeptides of the present invention can also be used to raise polyclonal and monoclonal antibodies, which are useful in assays for detecting Neutrokin  $\alpha$  protein expression as described

below or as agonists and antagonists capable of enhancing or inhibiting Neutrokin  $\alpha$  protein function. Further, such polypeptides can be used in the yeast two-hybrid system to "capture" Neutrokin  $\alpha$  protein binding proteins which are also candidate agonists and antagonists according to the present invention. The yeast two hybrid system is described in Fields and Song, *Nature* 340:245-246 (1989).

### ***Epitope-Bearing Portions***

In another aspect, the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983).

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G., Shinnick, T. M., Green, N. and Learner, R. A. (1983) "Antibodies that react with predetermined sites on proteins", *Science*, 219:660-666. Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal

antibodies, that bind specifically to a polypeptide of the invention. See, for instance, Wilson *et al.*, *Cell* 37:767-778 (1984) at 777.

Antigenic epitope-bearing peptides and polypeptides of the invention preferably contain a sequence of at least seven, more preferably at least nine and most preferably between about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.

Non-limiting examples of antigenic polypeptides or peptides that can be used to generate Neutrokin specific antibodies include: a polypeptide comprising amino acid residues from about Phe 115 to about Leu 147 in Figure 1 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ile 150 to about Tyr 163 in Figure 1 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ser 171 to about Phe 194 in Figure 1 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Glu 223 to about Tyr 247 in Figure 1 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ser 271 to about Phe 278 in Figure 1 (SEQ ID NO:2); These polypeptide fragments have been determined to bear antigenic epitopes of the Neutrokin  $\alpha$  protein by the analysis of the Jameson-Wolf antigenic index, as shown in Figure 3, above.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means. See, e.g., Houghten, R. A. (1985) General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. *Proc. Natl. Acad. Sci. USA* 82:5131-5135; this "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten et al. (1986).

Epitope-bearing peptides and polypeptides of the invention are used to induce antibodies according to methods well known in the art. See, for instance, Sutcliffe et al., *supra*; Wilson et al., *supra*; Chow, M. et al., *Proc. Natl. Acad. Sci. USA* 82:910-914; and Bittle, F. J. et al., *J. Gen. Virol.* 66:2347-2354 (1985). Immunogenic epitope-bearing peptides of the

4

invention, i.e., those parts of a protein that elicit an antibody response when the whole protein is the immunogen, are identified according to methods known in the art. See, for instance, Geysen et al., *supra*. Further still, U.S. Patent No. 5,194,392 to Geysen (1990) describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (i.e., a "mimotope") which is complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, U.S. Patent No. 4,433,092 to Geysen (1989) describes a method of detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent No. 5,480,971 to Houghten, R. A. et al. (1996) on Peralkylated Oligopeptide Mixtures discloses linear C1-C7-alkyl peralkylated oligopeptides and sets and libraries of such peptides, as well as methods for using such oligopeptide sets and libraries for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest. Thus, non-peptide analogs of the epitope-bearing peptides of the invention also can be made routinely by these methods.

### ***Fusion Proteins***

As one of skill in the art will appreciate, Neutrokin  $\alpha$  polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. This has been shown, e.g., for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988)). Fusion proteins that have a disulfide-linked dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than the monomeric Neutrokin  $\alpha$  protein or

protein fragment alone (Fountoulakis et al., *J. Biochem.* 270:3958-3964 (1995)).

### *Immune System-Related Disorder Diagnosis*

The present inventors have discovered that Neutrokin  $\alpha$  is expressed in various tissues and particularly in neutrophils. For a number of immune system-related disorders, substantially altered (increased or decreased) levels of Neutrokin  $\alpha$  gene expression can be detected in immune system tissue or other cells or bodily fluids (e.g., sera, plasma, urine, synovial fluid or spinal fluid) taken from an individual having such a disorder, relative to a "standard" Neutrokin  $\alpha$  gene expression level, that is, the Neutrokin  $\alpha$  expression level in immune system tissues or bodily fluids from an individual not having the immune system disorder. Thus, the invention provides a diagnostic method useful during diagnosis of an immune system disorder, which involves measuring the expression level of the gene encoding the Neutrokin  $\alpha$  protein in immune system tissue or other cells or body fluid from an individual and comparing the measured gene expression level with a standard Neutrokin  $\alpha$  gene expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of an immune system disorder.

In particular, it is believed that certain tissues in mammals with cancer of the immune express significantly enhanced or reduced levels of the Neutrokin  $\alpha$  protein and mRNA encoding the Neutrokin  $\alpha$  protein when compared to a corresponding "standard" level. Further, it is believed that enhanced or depressed levels of the Neutrokin  $\alpha$  protein can be detected in certain body fluids (e.g., sera, plasma, urine, and spinal fluid) from mammals with such a cancer when compared to sera from mammals of the same species not having the cancer.

Thus, the invention provides a diagnostic method useful during diagnosis of an immune system disorder, including cancers of this system, which involves measuring the expression level of the gene encoding the Neutrokin  $\alpha$  protein in immune system tissue or other cells or body fluid

43

from an individual and comparing the measured gene expression level with a standard Neutrokin  $\alpha$  gene expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of an immune system disorder.

5           Where a diagnosis of a disorder in the immune system, including diagnosis of a tumor, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed Neutrokin  $\alpha$  gene expression will experience a worse clinical outcome relative to patients expressing the gene at a  
10           level nearer the standard level.

          By "assaying the expression level of the gene encoding the Neutrokin  $\alpha$  protein" is intended qualitatively or quantitatively measuring or estimating the level of the Neutrokin  $\alpha$  protein or the level of the mRNA encoding the Neutrokin  $\alpha$  protein in a first biological sample either directly (e.g., by  
15           determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the Neutrokin  $\alpha$  protein level or mRNA level in a second biological sample). Preferably, the Neutrokin  $\alpha$  protein level or mRNA level in the first biological sample is measured or estimated and compared to a standard Neutrokin  $\alpha$  protein level or mRNA level, the  
20           standard being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder of the immune system. As will be appreciated in the art, once a standard Neutrokin  $\alpha$  protein level or mRNA level is known, it can be used repeatedly as a standard for comparison.

25           By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains Neutrokin  $\alpha$  protein or mRNA. As indicated, biological samples include body fluids (such as sera, plasma, urine, synovial fluid and spinal fluid) which contain free extracellular domains of the Neutrokin  $\alpha$  protein, immune  
30           system tissue, and other tissue sources found to express complete or free

**THIS PAGE BLANK (USPTO)**



44

extracellular domain of the Neutrokin  $\alpha$  or a Neutrokin  $\alpha$  receptor.

Methods for obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

5           The present invention is useful for diagnosis or treatment of various immune system-related disorders in mammals, preferably humans. Such disorders include but are not limited to tumors and tumor metastasis, infections by bacteria, viruses and other parasites, immunodeficiencies, inflammatory diseases, lymphadenopathy, autoimmune diseases, and graft  
10       versus host disease.

          Total cellular RNA can be isolated from a biological sample using any suitable technique such as the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, *Anal. Biochem.* 162:156-159 (1987). Levels of mRNA encoding the Neutrokin  $\alpha$  protein are  
15       then assayed using any appropriate method. These include Northern blot analysis, S1 nuclease mapping, the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

20           Assaying Neutrokin  $\alpha$  protein levels in a biological sample can occur using antibody-based techniques. For example, Neutrokin  $\alpha$  protein expression in tissues can be studied with classical immunohistological methods (Jalkanen, M., *et al.*, *J. Cell. Biol.* 101:976-985 (1985); Jalkanen, M., *et al.*, *J. Cell. Biol.* 105:3087-3096 (1987)). Other antibody-based methods useful for  
25       detecting Neutrokin  $\alpha$  protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ),  
30       and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying Neutrokin  $\alpha$  protein levels in a biological sample obtained from an individual, Neutrokin  $\alpha$  protein can also be detected *in vivo* by imaging. Antibody labels or markers for *in vivo* imaging of Neutrokin  $\alpha$  protein include those detectable by X-radiography, NMR or ESR. For X-radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

A Neutrokin  $\alpha$  protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously or intraperitoneally) into the mammal to be examined for immune system disorder. It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain Neutrokin  $\alpha$  protein. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments" (Chapter 13 in *Tumor Imaging: The Radiochemical Detection of Cancer*, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982)).

### ***Antibodies***

Neutrokin  $\alpha$ -protein specific antibodies for use in the present invention can be raised against the intact Neutrokin  $\alpha$  protein or an antigenic polypeptide fragment thereof, which may be presented together with a carrier

46

protein, such as an albumin, to an animal system (such as rabbit or mouse) or, if it is long enough (at least about 25 amino acids), without a carrier.

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')<sub>2</sub> fragments) which are capable of specifically binding to Neutrokin  $\alpha$  protein. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl et al., *J. Nucl. Med.* 24:316-325 (1983)). Thus, these fragments are preferred.

The antibodies of the present invention may be prepared by any of a variety of methods. For example, cells expressing the Neutrokin  $\alpha$  protein or an antigenic fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of Neutrokin  $\alpha$  protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or Neutrokin  $\alpha$  protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., (1981) pp. 563-681). In general, such procedures involve immunizing an animal (preferably a mouse) with a Neutrokin  $\alpha$  protein antigen or, more preferably, with a Neutrokin  $\alpha$  protein-expressing cell. Suitable cells can be recognized by their capacity to bind anti-Neutrokin  $\alpha$  protein antibody. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56° C), and supplemented with about 10 g/l

47

of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100  $\mu$ g/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the American Type Culture Collection, Rockville, Maryland. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the Neutrokin  $\alpha$  protein antigen.

Alternatively, additional antibodies capable of binding to the Neutrokin  $\alpha$  protein antigen may be produced in a two-step procedure through the use of anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and that, therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, Neutrokin  $\alpha$ -protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the Neutrokin  $\alpha$  protein-specific antibody can be blocked by the Neutrokin  $\alpha$  protein antigen. Such antibodies comprise anti-idiotypic antibodies to the Neutrokin  $\alpha$  protein-specific antibody and can be used to immunize an animal to induce formation of further Neutrokin  $\alpha$  protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, Neutrokin  $\alpha$  protein-binding

48

fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

Where *in vivo* imaging is used to detect enhanced levels of Neutrokin  $\alpha$  protein for diagnosis in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. See, for review, Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., *Nature* 312:643 (1984); Neuberger et al., *Nature* 314:268 (1985).

### *Treatment of Immune System-Related Disorders*

As noted above, Neutrokin  $\alpha$  polynucleotides and polypeptides are useful for diagnosis of conditions involving abnormally high or low expression of Neutrokin  $\alpha$  activities. Given the cells and tissues where Neutrokin  $\alpha$  is expressed as well as the activities modulated by Neutrokin  $\alpha$ , it is readily apparent that a substantially altered (increased or decreased) level of expression of Neutrokin  $\alpha$  in an individual compared to the standard or "normal" level produces pathological conditions related to the bodily system(s) in which Neutrokin  $\alpha$  is expressed and/or is active.

It will also be appreciated by one of ordinary skill that, since the Neutrokin  $\alpha$  protein of the invention is a member of the TNF family, the extracellular domain of the protein may be released in soluble form from the cells which express Neutrokin  $\alpha$  by proteolytic cleavage and therefore, when Neutrokin  $\alpha$  protein (particularly a soluble form of the extracellular domain) is added from an exogenous source to cells, tissues or the body of an individual, the protein will exert its modulating activities on any of its target cells of that individual. Also, cells expressing this type II transmembrane

protein may be added to cells, tissues or the body of an individual whereby the added cells will bind to cells expressing receptor for Neutrokin  $\alpha$  whereby the cells expressing Neutrokin  $\alpha$  can cause actions (e.g., cytotoxicity) on the receptor-bearing target cells.

5           Therefore, it will be appreciated that conditions caused by a decrease in the standard or normal level of Neutrokin  $\alpha$  activity in an individual, particularly disorders of the immune system, can be treated by administration of Neutrokin  $\alpha$  protein (in the form of soluble extracellular domain or cells expressing the complete protein). Thus, the invention also provides a method  
10 of treatment of an individual in need of an increased level of Neutrokin  $\alpha$  activity comprising administering to such an individual a pharmaceutical composition comprising an amount of an isolated Neutrokin  $\alpha$  polypeptide of the invention, effective to increase the Neutrokin  $\alpha$  activity level in such an individual.

15           Since Neutrokin  $\alpha$  belongs to the TNF superfamily, it also should also modulate angiogenesis. In addition, since Neutrokin  $\alpha$  inhibits immune cell functions, it will have a wide range of anti-inflammatory activities. Neutrokin  $\alpha$  may be employed as an anti-neovascularizing agent to treat solid tumors by stimulating the invasion and activation of host defense cells, e.g.,  
20 cytotoxic T cells and macrophages and by inhibiting the angiogenesis of tumors. Those of skill in the art will recognize other non-cancer indications where blood vessel proliferation is not wanted. They may also be employed to enhance host defenses against resistant chronic and acute infections, for example, myobacterial infections via the attraction and activation of  
25 microbicidal leukocytes. Neutrokin  $\alpha$  may also be employed to inhibit T-cell proliferation by the inhibition of IL-2 biosynthesis for the treatment of T-cell mediated auto-immune diseases and lymphocytic leukemias. Neutrokin  $\alpha$  may also be employed to stimulate wound healing, both via the recruitment of debris clearing and connective tissue promoting inflammatory cells. In this  
30 same manner, Neutrokin  $\alpha$  may also be employed to treat other fibrotic

50

disorders, including liver cirrhosis, osteoarthritis and pulmonary fibrosis.

Neutrokin  $\alpha$  also increases the presence of eosinophils which have the distinctive function of killing the larvae of parasites that invade tissues, as in schistosomiasis, trichinosis and ascariasis. It may also be employed to regulate hematopoiesis, by regulating the activation and differentiation of various hematopoietic progenitor cells, for example, to release mature leukocytes from the bone marrow following chemotherapy, i.e., in stem cell mobilization. Neutrokin  $\alpha$  may also be employed to treat sepsis.

### *Formulations*

The Neutrokin  $\alpha$  polypeptide composition (preferably containing a polypeptide which is a soluble form of the extracellular domain) will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with Neutrokin  $\alpha$  polypeptide alone), the site of delivery of the Neutrokin  $\alpha$  polypeptide composition, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" of Neutrokin  $\alpha$  polypeptide for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of Neutrokin  $\alpha$  polypeptide administered parenterally per dose will be in the range of about 1  $\mu\text{g/kg/day}$  to 10  $\text{mg/kg/day}$  of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01  $\text{mg/kg/day}$ , and most preferably for humans between about 0.01 and 1  $\text{mg/kg/day}$  for the hormone. If given continuously, the Neutrokin  $\alpha$  polypeptide is typically administered at a dose rate of about 1  $\mu\text{g/kg/hour}$  to about 50  $\mu\text{g/kg/hour}$ , either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the Neutrokin  $\alpha$  of the invention may be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), buccally, or as an oral or nasal spray. By

5 "pharmaceutically acceptable carrier" is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

10 The Neutrokin  $\alpha$  polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic

15 acid and gamma-ethyl-L-glutamate (Sidman, U. et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and R. Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release Neutrokin  $\alpha$

20 polypeptide compositions also include liposomally entrapped Neutrokin  $\alpha$  polypeptide. Liposomes containing Neutrokin  $\alpha$  polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. (USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP

25 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Neutrokin  $\alpha$  polypeptide therapy.



For parenteral administration, in one embodiment, the Neutrokin  $\alpha$  polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

Generally, the formulations are prepared by contacting the Neutrokin  $\alpha$  polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Neutrokin  $\alpha$  polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of

5 Neutrokin  $\alpha$  polypeptide salts.

Neutrokin  $\alpha$  polypeptide to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic Neutrokin  $\alpha$  polypeptide compositions generally are placed into a container having a sterile

10 access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Neutrokin  $\alpha$  polypeptide ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a

15 lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Neutrokin  $\alpha$  polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Neutrokin  $\alpha$  polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising

20 one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological

25 products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

*Agonists and Antagonists - Assays and Molecules*

The invention also provides a method of screening compounds to identify those which enhance or block the action of Neutrokin  $\alpha$  on cells, such as its interaction with Neutrokin  $\alpha$  binding molecules such as receptor molecules. An agonist is a compound which increases the natural biological functions of Neutrokin  $\alpha$  or which functions in a manner similar to Neutrokin while antagonists decrease or eliminate such functions.

In another aspect of this embodiment the invention provides a method for identifying a receptor protein or other ligand-binding protein which binds specifically to a Neutrokin  $\alpha$  polypeptide. For example, a cellular compartment, such as a membrane or a preparation thereof, may be prepared from a cell that expresses a molecule that binds Neutrokin  $\alpha$ . The preparation is incubated with labeled Neutrokin  $\alpha$  and complexes of Neutrokin  $\alpha$  bound to the receptor or other binding protein are isolated and characterized according to routine methods known in the art. Alternatively, the Neutrokin  $\alpha$  polypeptide may be bound to a solid support so that binding molecules solubilized from cells are bound to the column and then eluted and characterized according to routine methods.

In the assay of the invention for agonists or antagonists, a cellular compartment, such as a membrane or a preparation thereof, may be prepared from a cell that expresses a molecule that binds Neutrokin  $\alpha$  such as a molecule of a signaling or regulatory pathway modulated by Neutrokin  $\alpha$ . The preparation is incubated with labeled Neutrokin  $\alpha$  in the absence or the presence of a candidate molecule which may be a Neutrokin  $\alpha$  agonist or antagonist. The ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labeled ligand. Molecules which bind gratuitously, i.e., without inducing the effects of Neutrokin  $\alpha$  on binding the Neutrokin  $\alpha$  binding molecule, are most likely to be good antagonists. Molecules that bind well and elicit effects that are the same as or closely related to Neutrokin  $\alpha$  are agonists.

Neutrokin  $\alpha$ -like effects of potential agonists and antagonists may be measured, for instance, by determining activity of a second messenger system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of Neutrokin  $\alpha$  or molecules that elicit the same effects as Neutrokin  $\alpha$ . Second messenger systems that may be useful in this regard include but are not limited to AMP guanylate cyclase, ion channel or phosphoinositide hydrolysis second messenger systems.

Another example of an assay for Neutrokin  $\alpha$  antagonists is a competitive assay that combines Neutrokin  $\alpha$  and a potential antagonist with membrane-bound receptor molecules or recombinant Neutrokin  $\alpha$  receptor molecules under appropriate conditions for a competitive inhibition assay. Neutrokin  $\alpha$  can be labeled, such as by radioactivity, such that the number of Neutrokin  $\alpha$  molecules bound to a receptor molecule can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a receptor molecule, without inducing Neutrokin  $\alpha$  induced activities, thereby preventing the action of Neutrokin  $\alpha$  by excluding Neutrokin  $\alpha$  from binding.

Other potential antagonists include antisense molecules. Antisense technology can be used to control gene expression through antisense DNA or RNA or through triple-helix formation. Antisense techniques are discussed, for example, in Okano, J. Neurochem. 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., Nucleic Acids Research 6: 3073 (1979); Cooney et al., Science 241: 456 (1988); and Dervan

et al., Science 251: 1360 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA. For example, the 5' coding portion of a polynucleotide that encodes the extracellular domain of the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of Neutrokin  $\alpha$ . The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into Neutrokin  $\alpha$  polypeptide. The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of Neutrokin  $\alpha$ .

The agonists and antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described above.

The antagonists may be employed for instance to inhibit Neutrokin  $\alpha$  the chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain auto-immune and chronic inflammatory and infective diseases. Examples of auto-immune diseases include multiple sclerosis, and insulin-dependent diabetes. The antagonists may also be employed to treat infectious diseases including silicosis, sarcoidosis, idiopathic pulmonary fibrosis by preventing the recruitment and activation of mononuclear phagocytes. They may also be employed to treat idiopathic hyper-eosinophilic syndrome by preventing eosinophil production and migration. Endotoxic shock may also be treated by the antagonists by preventing the migration of macrophages and their production of the human chemokine polypeptides of the present invention. The antagonists may also be employed for treating atherosclerosis, by preventing monocyte infiltration in the artery wall. The antagonists may also be employed to treat histamine-mediated allergic reactions and immunological

disorders including late phase allergic reactions, chronic urticaria, and atopic dermatitis by inhibiting chemokine-induced mast cell and basophil degranulation and release of histamine. IgE-mediated allergic reactions such as allergic asthma, rhinitis, and eczema may also be treated. The antagonists may also be employed to treat chronic and acute inflammation by preventing the attraction of monocytes to a wound area. They may also be employed to regulate normal pulmonary macrophage populations, since chronic and acute inflammatory pulmonary diseases are associated with sequestration of mononuclear phagocytes in the lung. Antagonists may also be employed to treat rheumatoid arthritis by preventing the attraction of monocytes into synovial fluid in the joints of patients. Monocyte influx and activation plays a significant role in the pathogenesis of both degenerative and inflammatory arthropathies. The antagonists may be employed to interfere with the deleterious cascades attributed primarily to IL-1 and TNF, which prevents the biosynthesis of other inflammatory cytokines. In this way, the antagonists may be employed to prevent inflammation. The antagonists may also be employed to inhibit prostaglandin-independent fever induced by chemokines. The antagonists may also be employed to treat cases of bone marrow failure, for example, aplastic anemia and myelodysplastic syndrome. The antagonists may also be employed to treat asthma and allergy by preventing eosinophil accumulation in the lung. The antagonists may also be employed to treat subepithelial basement membrane fibrosis which is a prominent feature of the asthmatic lung.

Antibodies against Neutrokin  $\alpha$  may be employed to bind to and inhibit Neutrokin  $\alpha$  activity to treat ARDS, by preventing infiltration of neutrophils into the lung after injury. The antagonists may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as hereinafter described.]

*Chromosome Assays*

The nucleic acid molecules of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

In certain preferred embodiments in this regard, the cDNA herein disclosed is used to clone genomic DNA of a Neutrokin  $\alpha$  protein gene. This can be accomplished using a variety of well known techniques and libraries, which generally are available commercially. The genomic DNA then is used for *in situ* chromosome mapping using well known techniques for this purpose.

In addition, in some cases, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the cDNA. Computer analysis of the 3' untranslated region of the gene is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Fluorescence *in situ* hybridization ("FISH") of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with probes from the cDNA as short as 50 or 60 bp. For a review of this technique, see Verma *et al.*, *Human Chromosomes: A Manual Of Basic Techniques*, Pergamon Press, New York (1988).

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated

with genetic map data. Such data are found, for example, in V. McKusick, *Mendelian Inheritance In Man*, available on-line through Johns Hopkins University, Welch Medical Library. The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

### *Examples*

#### *Example 1a: Expression and Purification of "His-tagged" Neutrokin $\alpha$ in *E. coli**

The bacterial expression vector pQE9 (pD10) is used for bacterial expression in this example. (QIAGEN, Inc., *supra*). pQE9 encodes ampicillin antibiotic resistance ("Ampr") and contains a bacterial origin of replication ("ori"), an IPTG inducible promoter, a ribosome binding site ("RBS"), six codons encoding histidine residues that allow affinity purification using nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin sold by QIAGEN, Inc., *supra*, and suitable single restriction enzyme cleavage sites. These elements are arranged such that an inserted DNA fragment encoding a polypeptide expresses that polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the amino terminus of that polypeptide.

The DNA sequence encoding the desired portion of the Neutrokin  $\alpha$  protein comprising the extracellular domain sequence is amplified from the deposited cDNA clone using PCR oligonucleotide primers which anneal to the amino terminal sequences of the desired portion of the Neutrokin  $\alpha$  protein



60

and to sequences in the deposited construct 3' to the cDNA coding sequence.

Additional nucleotides containing restriction sites to facilitate cloning in the pQE9 vector are added to the 5' and 3' primer sequences, respectively.

For cloning the extracellular domain of the protein, the 5' primer has the sequence 5' GTGGGATCCAGCCTCCGGGCAGAGCTG 3' (SEQ ID NO:10) containing the underlined BamH I restriction site followed by 18 nucleotides of the amino terminal coding sequence of the extracellular domain of the Neutrokin  $\alpha$  sequence in Figure 1. One of ordinary skill in the art would appreciate, of course, that the point in the protein coding sequence where the 5' primer begins may be varied to amplify a DNA segment encoding any desired portion of the complete Neutrokin  $\alpha$  protein shorter or longer than the extracellular domain of the form. The 3' primer has the sequence 5' GTGAAGCTTTTATTACAGCAGTTTCAATGCACC3' (SEQ ID NO:11) containing the underlined Hind III restriction site followed by two stop codons and 18 nucleotides complementary to the 3' end of the coding sequence of the Neutrokin  $\alpha$  DNA sequence in Figure 1.

The amplified Neutrokin  $\alpha$  DNA fragment and the vector pQE9 are digested with BamH I and Hind III and the digested DNAs are then ligated together. Insertion of the Neutrokin  $\alpha$  DNA into the restricted pQE9 vector places the Neutrokin  $\alpha$  protein coding region downstream from the IPTG-inducible promoter and in-frame with an initiating AUG and the six histidine codons.

The ligation mixture is transformed into competent *E. coli* cells using standard procedures such as those described in Sambrook et al., *Molecular Cloning: a Laboratory Manual, 2nd Ed.*; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989). *E. coli* strain M15/rep4, containing multiple copies of the plasmid pREP4, which expresses the lac repressor and confers kanamycin resistance ("Kan<sup>r</sup>"), is used in carrying out the illustrative example described herein. This strain, which is only one of many that are

61

suitable for expressing Neutrokin  $\alpha$  protein, is available commercially from QIAGEN, Inc., *supra*. Transformants are identified by their ability to grow on LB plates in the presence of ampicillin and kanamycin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing. Clones containing the desired constructs are grown overnight ("O/N") in liquid culture in LB media supplemented with both ampicillin (100  $\mu$ g/ml) and kanamycin (25  $\mu$ g/ml). The O/N culture is used to inoculate a large culture, at a dilution of approximately 1:25 to 1:250. The cells are grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. Isopropyl- $\beta$ -D-thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM to induce transcription from the lac repressor sensitive promoter, by inactivating the lacI repressor. Cells subsequently are incubated further for 3 to 4 hours. Cells then are harvested by centrifugation.

The cells are then stirred for 3-4 hours at 4° C in 6M guanidine-HCl, pH 8. The cell debris is removed by centrifugation, and the supernatant containing the Neutrokin  $\alpha$  is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist, 1995, QIAGEN, Inc., *supra*). Briefly the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the Neutrokin  $\alpha$  is eluted with 6 M guanidine-HCl, pH 5.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as

62

follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4° C or frozen at -80° C.

***Example 1b: Expression and Purification of Neutrokin  $\alpha$  in *E. coli****

The bacterial expression vector pQE60 is used for bacterial expression in this example. (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311). pQE60 encodes ampicillin antibiotic resistance ("Ampr") and contains a bacterial origin of replication ("ori"), an IPTG inducible promoter, a ribosome binding site ("RBS"), six codons encoding histidine residues that allow affinity purification using nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin sold by QIAGEN, Inc., *supra*, and suitable single restriction enzyme cleavage sites. These elements are arranged such that a DNA fragment encoding a polypeptide may be inserted in such as way as to produce that polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the carboxyl terminus of that polypeptide. However, in this example, the polypeptide coding sequence is inserted such that translation of the six His codons is prevented and, therefore, the polypeptide is produced with no 6 X His tag.

The DNA sequence encoding the desired portion of the Neutrokin  $\alpha$  protein comprising the extracellular domain sequence is amplified from the deposited cDNA clone using PCR oligonucleotide primers which anneal to the amino terminal sequences of the desired portion of the Neutrokin  $\alpha$  protein and to sequences in the deposited construct 3' to the cDNA coding sequence.

63

Additional nucleotides containing restriction sites to facilitate cloning in the pQE60 vector are added to the 5' and 3' sequences, respectively.

For cloning the extracellular domain of the protein, the 5' primer has the sequence 5' GTGTCATGAGCCTCCGGGCAGAGCTG 3' (SEQ ID NO:12) containing the underlined BspH restriction site followed by 17 nucleotides of the amino terminal coding sequence of the extracellular domain of the Neutrokin  $\alpha$  sequence in Figure 1. One of ordinary skill in the art would appreciate, of course, that the point in the protein coding sequence where the 5' primer begins may be varied to amplify a desired portion of the complete protein shorter or longer than the extracellular domain of the form. The 3' primer has the sequence

5'GTGAAGCTTTTATTACAGCAGTTTCAATGCACC 3' (SEQ ID NO:13) containing the underlined Hind III restriction site followed by two stop codons and 18 nucleotides complementary to the 3' end of the coding sequence in the Neutrokin  $\alpha$  DNA sequence in Figure 1.

The amplified Neutrokin  $\alpha$  DNA fragments and the vector pQE60 are digested with BspH I and Hind III and the digested DNAs are then ligated together. Insertion of the Neutrokin  $\alpha$  DNA into the restricted pQE60 vector places the Neutrokin  $\alpha$  protein coding region including its associated stop codon downstream from the IPTG-inducible promoter and in-frame with an initiating AUG. The associated stop codon prevents translation of the six histidine codons downstream of the insertion point.

The ligation mixture is transformed into competent *E. coli* cells using standard procedures such as those described in Sambrook et al., *Molecular Cloning: a Laboratory Manual, 2nd Ed.*; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989). *E. coli* strain M15/rep4, containing multiple copies of the plasmid pREP4, which expresses the lac repressor and confers kanamycin resistance ("Kanr"), is used in carrying out the illustrative example described herein. This strain, which is only one of many that are

64

suitable for expressing Neutrokin  $\alpha$  protein, is available commercially from QIAGEN, Inc., *supra*. Transformants are identified by their ability to grow on LB plates in the presence of ampicillin and kanamycin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

Clones containing the desired constructs are grown overnight ("O/N") in liquid culture in LB media supplemented with both ampicillin (100  $\mu$ g/ml) and kanamycin (25  $\mu$ g/ml). The O/N culture is used to inoculate a large culture, at a dilution of approximately 1:25 to 1:250. The cells are grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. isopropyl-b-D-thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM to induce transcription from the lac repressor sensitive promoter, by inactivating the lacI repressor. Cells subsequently are incubated further for 3 to 4 hours. Cells then are harvested by centrifugation.

The cells are then stirred for 3-4 hours at 4° C in 6M guanidine-HCl, pH 8. The cell debris is removed by centrifugation, and the supernatant containing the Neutrokin  $\alpha$  is dialyzed against 50 mM Na-acetate buffer pH 6, supplemented with 200 mM NaCl. Alternatively, the protein can be successfully refolded by dialyzing it against 500 mM NaCl, 20% glycerol, 25 mM Tris/HCl pH 7.4, containing protease inhibitors. After renaturation the protein can be purified by ion exchange, hydrophobic interaction and size exclusion chromatography. Alternatively, an affinity chromatography step such as an antibody column can be used to obtain pure Neutrokin  $\alpha$  protein. The purified protein is stored at 4° C or frozen at -80° C.

***Example 2: Cloning and Expression of Neutrokin  $\alpha$  Protein in a Baculovirus Expression System***

In this illustrative example, the plasmid shuttle vector pA2 GP is used to insert the cloned DNA encoding the extracellular domain of the protein, lacking its naturally associated intracellular and transmembrane sequences, into

65

a baculovirus to express the extracellular domain of the Neutrokin  $\alpha$  protein, using a baculovirus leader and standard methods as described in Summers et al., *A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures*, Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

5 This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by the secretory signal peptide (leader) of the baculovirus gp67 protein and convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient  
10 polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type  
15 viral DNA to generate viable virus that expresses the cloned polynucleotide.

Many other baculovirus vectors could be used in place of the vector above, such as pAc373, pVL941 and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal  
20 peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

The cDNA sequence encoding the extracellular domain of the Neutrokin  $\alpha$  protein in the deposited clone, lacking the AUG initiation codon and the naturally associated intracellular and transmembrane domain sequences  
25 shown in Figure 1 (SEQ ID NO:2), is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. The 5' primer has the sequence 5' GTGGGATCCCCGGGCAGAGCTGCAGGGC 3' (SEQ ID NO:14) containing the underlined BamH I restriction enzyme site followed by 18 nucleotides of the sequence of the extracellular domain of the

66

Neutrokin  $\alpha$  protein shown in Figure 1, beginning with the indicated N-terminus of the extracellular domain of the protein. The 3' primer has the sequence 5' GTGGGATCCTTATTACAGCAGTTTCAATGCACC 3' (SEQ ID NO:15) containing the underlined Bam HI restriction site followed by two stop codons and 18 nucleotides complementary to the 3' coding sequence in Figure 1.

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with BamH I and again is purified on a 1% agarose gel. This fragment is designated herein F1.

The plasmid is digested with the restriction enzymes Bam HI and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("GeneClean" BIO 101 Inc., La Jolla, Ca.). This vector DNA is designated herein "V1".

Fragment F1 and the dephosphorylated plasmid V1 are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Statagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria are identified that contain the plasmid with the human Neutrokin  $\alpha$  gene by digesting DNA from individual colonies using Bam HI and then analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing. This plasmid is designated herein pA2GP Neutrokin  $\alpha$ .

Five  $\mu$ g of the plasmid pA2GP Neutrokin  $\alpha$  is co-transfected with 1.0  $\mu$ g of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., *Proc. Natl. Acad. Sci. USA* 84: 7413-7417 (1987). One  $\mu$ g of BaculoGold™ virus DNA and 5  $\mu$ g of the

67

plasmid pA2GP Neutrokin  $\alpha$  are mixed in a sterile well of a microtiter plate containing 50  $\mu$ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10  $\mu$ l Lipofectin plus 90  $\mu$ l Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10). After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200  $\mu$ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C. The recombinant virus is called V-Neutrokin  $\alpha$ .

To verify the expression of the Neutrokin  $\alpha$  gene Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus V-Neutrokin  $\alpha$  at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus



methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5  $\mu$ Ci of  $^{35}$ S-methionine and 5  $\mu$ Ci  $^{35}$ S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the extracellular domain of the protein and thus the cleavage point and length of the secretory signal peptide.

***Example 3: Cloning and Expression of Neutrokin  $\alpha$  in Mammalian Cells***

A typical mammalian expression vector contains the promoter element, which mediates the initiation of transcription of mRNA, the protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription can be achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter). Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146) and pBC12MI (ATCC 67109). Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the gene can be expressed in stable cell lines that contain the gene integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

5 The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful to develop cell lines that carry several hundred or even several thousand copies of the gene of interest. Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., *Biochem J.* 227:277-279 (1991); Bebbington et  
10 al., *Bio/Technology* 10:169-175 (1992)). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

15 The expression vectors pC1 and pC4 contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., *Molecular and Cellular Biology*, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., *Cell* 41:521-530 (1985)). Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the  
20 cloning of the gene of interest. The vectors contain in addition the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene.

#### ***Example 3(a): Cloning and Expression in COS Cells***

The expression plasmid, pNeutrokin  $\alpha$  HA, is made by cloning a portion of the deposited cDNA encoding the extracellular domain of the  
25 Neutrokin  $\alpha$  protein into the expression vector pcDNAI/Amp or pcDNAIII (which can be obtained from Invitrogen, Inc.). To produce a soluble, secreted form of the polypeptide, the extracellular domain is fused to the secretory leader sequence of the human IL-6 gene.

The expression vector pcDNAI/amp contains: (1) an *E. coli* origin of replication effective for propagation in *E. coli* and other prokaryotic cells; (2) an ampicillin resistance gene for selection of plasmid-containing prokaryotic cells; (3) an SV40 origin of replication for propagation in eukaryotic cells; (4) a CMV promoter, a polylinker, an SV40 intron; (5) several codons encoding a hemagglutinin fragment (i.e., an "HA" tag to facilitate purification) followed by a termination codon and polyadenylation signal arranged so that a cDNA can be conveniently placed under expression control of the CMV promoter and operably linked to the SV40 intron and the polyadenylation signal by means of restriction sites in the polylinker. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein described by Wilson et al., *Cell* 37: 767 (1984). The fusion of the HA tag to the target protein allows easy detection and recovery of the recombinant protein with an antibody that recognizes the HA epitope. pcDNAIII contains, in addition, the selectable neomycin marker.

A DNA fragment encoding the extracellular domain of the Neutrokin  $\alpha$  polypeptide is cloned into the polylinker region of the vector so that recombinant protein expression is directed by the CMV promoter. The plasmid construction strategy is as follows. The Neutrokin  $\alpha$  cDNA of the deposited clone is amplified using primers that contain convenient restriction sites, much as described above for construction of vectors for expression of Neutrokin  $\alpha$  in *E. coli*. Suitable primers include the following, which are used in this example. The 5' primer, containing the underlined Bam HI site, a Kozak sequence, an AUG start codon, a sequence encoding the secretory leader peptide from the human IL-6 gene, and 18 nucleotides of the 5' coding region of the extracellular domain of Neutrokin  $\alpha$  protein, has the following sequence:

5' GCGGGATCCGCCACCATGAACTCCTTCTCCACAAGCGCCTTCG  
GTCCAGTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTCCTGCTG

71

CCTTCCCTGCCCCAGTTGTGAGACAAGGGGACCTGGCCAGC3'

(SEQ ID NO:16). The 3' primer, containing the underlined Bam HI restriction site and 18 of nucleotides complementary to the 3' coding sequence immediately before the stop codon, has the following sequence:

5' GTGGGATCCTTACAGCAGTTTCAATGCACC 3' (SEQ ID NO:17).

The PCR amplified DNA fragment and the vector, pcDNAI/Amp, are digested with Bam HI and then ligated. The ligation mixture is transformed into *E. coli* strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037), and the transformed culture is plated on ampicillin media plates which then are incubated to allow growth of ampicillin resistant colonies. Plasmid DNA is isolated from resistant colonies and examined by restriction analysis or other means for the presence of the fragment encoding the Neutrokin  $\alpha$  extracellular domain.

For expression of recombinant Neutrokin  $\alpha$ , COS cells are transfected with an expression vector, as described above, using DEAE-DEXTRAN, as described, for instance, in Sambrook et al., *Molecular Cloning: a Laboratory Manual*, Cold Spring Laboratory Press, Cold Spring Harbor, New York (1989). Cells are incubated under conditions for expression of Neutrokin  $\alpha$  by the vector.

Expression of the Neutrokin  $\alpha$  HA fusion protein is detected by radiolabeling and immunoprecipitation, using methods described in, for example Harlow et al., *Antibodies: A Laboratory Manual, 2nd Ed.*; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988). To this end, two days after transfection, the cells are labeled by incubation in media containing  $^{35}\text{S}$ -cysteine for 8 hours. The cells and the media are collected, and the cells are washed and the lysed with detergent-containing RIPA buffer: 150 mM NaCl, 1% NP-40, 0.1% SDS, 1% NP-40, 0.5% DOC, 50 mM TRIS, pH 7.5, as described by Wilson et al. cited above. Proteins are precipitated from the cell lysate and from the culture media using an HA-specific monoclonal

72

antibody. The precipitated proteins then are analyzed by SDS-PAGE and autoradiography. An expression product of the expected size is seen in the cell lysate, which is not seen in negative controls.

**Example 3(b): Cloning and Expression in CHO Cells**

5           The vector pC4 is used for the expression of Neutrokin  $\alpha$  protein. Plasmid pC4 is a derivative of the plasmid pSV2-dhfr (ATCC Accession No. 37146). To produce a soluble, secreted form of the Neutrokin  $\alpha$  polypeptide, the portion of the deposited cDNA encoding the extracellular domain is fused to the secretory leader sequence of the human IL-6 gene. The vector plasmid contains the mouse DHFR gene under control of the SV40  
10           early promoter. Chinese hamster ovary- or other cells lacking dihydrofolate activity that are transfected with these plasmids can be selected by growing the cells in a selective medium (alpha minus MEM, Life Technologies) supplemented with the chemotherapeutic agent methotrexate. The  
15           amplification of the DHFR genes in cells resistant to methotrexate (MTX) has been well documented (see, e.g., Alt, F. W., Kellems, R. M., Bertino, J. R., and Schimke, R. T., 1978, *J. Biol. Chem.* 253:1357-1370, Hamlin, J. L. and Ma, C. 1990, *Biochem. et Biophys. Acta*, 1097:107-143, Page, M. J. and Sydenham, M. A. 1991, *Biotechnology* 9:64-68). Cells grown in increasing concentrations  
20           of MTX develop resistance to the drug by overproducing the target enzyme, DHFR, as a result of amplification of the DHFR gene. If a second gene is linked to the DHFR gene, it is usually co-amplified and over-expressed. It is known in the art that this approach may be used to develop cell lines carrying more than 1,000 copies of the amplified gene(s). Subsequently, when the  
25           methotrexate is withdrawn, cell lines are obtained which contain the amplified gene integrated into one or more chromosome(s) of the host cell.

Plasmid pC4 contains for expressing the gene of interest the strong promoter of the long terminal repeat (LTR) of the Rouse Sarcoma Virus

73

(Cullen, et al., *Molecular and Cellular Biology*, March 1985:438-447) plus a fragment isolated from the enhancer of the immediate early gene of human cytomegalovirus (CMV) (Boshart et al., *Cell* 41:521-530 (1985)).

Downstream of the promoter are the following single restriction enzyme cleavage sites that allow the integration of the genes: BamHI, Xba I, and Asp718. Behind these cloning sites the plasmid contains the 3' intron and polyadenylation site of the rat preproinsulin gene. Other high efficiency promoters can also be used for the expression, e.g., the human  $\beta$ -actin promoter, the SV40 early or late promoters or the long terminal repeats from other retroviruses, e.g., HIV and HTLV. Clontech's Tet-Off and Tet-On gene expression systems and similar systems can be used to express the Neutrokin  $\alpha$  in a regulated way in mammalian cells (Gossen, M., & Bujard, H. 1992, *Proc. Natl. Acad. Sci. USA* 89: 5547-5551). For the polyadenylation of the mRNA other signals, e.g., from the human growth hormone or globin genes can be used as well. Stable cell lines carrying a gene of interest integrated into the chromosomes can also be selected upon co-transfection with a selectable marker such as gpt, G418 or hygromycin. It is advantageous to use more than one selectable marker in the beginning, e.g., G418 plus methotrexate.

The plasmid pC4 is digested with the restriction enzymes Bam HI and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

The DNA sequence encoding the extracellular domain of the Neutrokin  $\alpha$  protein is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. The 5' primer, containing the underlined Bam HI site, a Kozak sequence, an AUG start codon, a sequence encoding the secretory leader peptide from the human IL-6 gene, and 18 nucleotides of the 5' coding region of the extracellular domain of Neutrokin  $\alpha$  protein, has the following sequence:

5' GCGGGATCCGCCACCATGAACTCCTTCTCCACAAGCGCCTTCG

74

GTCCAGTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTCCTGCTG  
CCTTCCCTGCCCCAGTTGTGAGACAAGGGGACCTGGCCAGC3'

(SEQ ID NO:16). The 3' primer, containing the underlined Bam HI and 18 of  
nucleotides complementary to the 3' coding sequence immediately before the  
stop codon, has the following sequence:

5' GTGGGATCCTTACAGCAGTTTCAATGCACC 3' (SEQ ID NO:17).

The amplified fragment is digested with the endonucleases Bam HI and  
then purified again on a 1% agarose gel. The isolated fragment and the  
dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101  
or XL-1 Blue cells are then transformed and bacteria are identified that contain  
the fragment inserted into plasmid pC4 using, for instance, restriction enzyme  
analysis.

Chinese hamster ovary cells lacking an active DHFR gene are used for  
transfection. Five µg of the expression plasmid pC4 is cotransfected with 0.5  
µg of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid  
pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5  
encoding an enzyme that confers resistance to a group of antibiotics including  
G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml  
G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning  
plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or  
50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single  
clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks  
using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400  
nM, 800 nM). Clones growing at the highest concentrations of methotrexate  
are then transferred to new 6-well plates containing even higher concentrations  
of methotrexate (1 µM, 2 µM, 5 µM, 10 mM, 20 mM). The same procedure  
is repeated until clones are obtained which grow at a concentration of 100 -  
200 µM. Expression of the desired gene product is analyzed, for instance, by  
SDS-PAGE and Western blot or by reversed phase HPLC analysis.

**Example 4: Tissue distribution of Neutrokin  $\alpha$  mRNA expression**

Northern blot analysis is carried out to examine Neutrokin  $\alpha$  gene expression in human tissues, using methods described by, among others, Sambrook *et al.*, cited above. A cDNA probe containing the entire nucleotide sequence of the Neutrokin  $\alpha$  protein (SEQ ID NO:1) is labeled with  $^{32}\text{P}$  using the *rediprime*<sup>TM</sup> DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using a CHROMA SPIN-100<sup>TM</sup> column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for Neutrokin  $\alpha$  mRNA.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) are obtained from Clontech and are examined with the labeled probe using ExpressHyb<sup>TM</sup> hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at  $-70^{\circ}\text{C}$  overnight, and films developed according to standard procedures.



76

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended  
5 claims.

The entire disclosure of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: YU, GUO-LIANG  
EBNER, REINHARD  
NI, JIAN
- (ii) TITLE OF INVENTION: NEUTROKINE ALPHA
- (iii) NUMBER OF SEQUENCES: 17
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: HUMAN GENOME SCIENCES, INC.
  - (B) STREET: 9410 KEY WEST AVENUE
  - (C) CITY: ROCKVILLE
  - (D) STATE: MD
  - (E) COUNTRY: US
  - (F) ZIP: 20850
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: BENSON, ROBERT H
  - (B) REGISTRATION NUMBER: 30,446
  - (C) REFERENCE/DOCKET NUMBER: PF343
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (301) 309-8504
  - (B) TELEFAX: (301) 309-8512

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1100 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
  - (A) NAME/KEY: CDS

(B) LOCATION: 147..1001

(ix) FEATURE:

(A) NAME/KEY: sig\_peptide

(B) LOCATION: 285..381

(ix) FEATURE:

(A) NAME/KEY: mat\_peptide

(B) LOCATION: 147..1001

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAATTCAAGGA TAACTCTCCT GAGGGGTGAG CCAAGCCCTG CCATGTAGTG CACGCAGGAC	60
ATCAACAAAC ACAGATAACA GGAAATGATC CATTCCCTGT GGTCATTAT TCTAAAGGCC	120
CCAACCTTCA AAGTTCAAGT AGTGAT ATG GAT GAC TCC ACA GAA AGG GAG CAG	173
Met Asp Asp Ser Thr Glu Arg Glu Gln	
1 5	
TCA CGC CTT ACT TCT TGC CTT AAG AAA AGA GAA GAA ATG AAA CTG AAG	221
Ser Arg Leu Thr Ser Cys Leu Lys Lys Arg Glu Glu Met Lys Leu Lys	
10 15 20 25	
GAG TGT GTT TCC ATC CTC CCA CGG AAG GAA AGC CCC TCT GTC CGA TCC	269
Glu Cys Val Ser Ile Leu Pro Arg Lys Glu Ser Pro Ser Val Arg Ser	
30 35 40	
TCC AAA GAC GGA AAG CTG CTG GCT GCA ACC TTG CTG CTG GCA CTG CTG	317
Ser Lys Asp Gly Lys Leu Leu Ala Ala Thr Leu Leu Leu Ala Leu Leu	
45 50 55	
TCT TGC TGC CTC ACG GTG GTG TCT TTC TAC CAG GTG GCC GCC CTG CAA	365
Ser Cys Cys Leu Thr Val Val Ser Phe Tyr Gln Val Ala Ala Leu Gln	
60 65 70	
GGG GAC CTG GCC AGC CTC CGG GCA GAG CTG CAG GGC CAC CAC GCG GAG	413
Gly Asp Leu Ala Ser Leu Arg Ala Glu Leu Gln Gly His His Ala Glu	
75 80 85	
AAG CTG CCA GCA GGA GCA GGA GCC CCC AAG GCC GGC CTG GAG GAA GCT	461
Lys Leu Pro Ala Gly Ala Gly Ala Pro Lys Ala Gly Leu Glu Glu Ala	
90 95 100 105	
CCA GCT GTC ACC GCG GGA CTG AAA ATC TTT GAA CCA CCA GCT CCA GGA	509
Pro Ala Val Thr Ala Gly Leu Lys Ile Phe Glu Pro Pro Ala Pro Gly	
110 115 120	
GAA GGC AAC TCC AGT CAG AAC AGC AGA AAT AAG CGT GCC GTT CAG GGT	557
Glu Gly Asn Ser Ser Gln Asn Ser Arg Asn Lys Arg Ala Val Gln Gly	
125 130 135	

CCA GAA GAA ACA GTC ACT CAA GAC TGC TTG CAA CTG ATT GCA GAC AGT Pro Glu Glu Thr Val Thr Gln Asp Cys Leu Gln Leu Ile Ala Asp Ser 140 145 150	605
GAA ACA CCA ACT ATA CAA AAA GGA TCT TAC ACA TTT GTT CCA TGG CTT Glu Thr Pro Thr Ile Gln Lys Gly Ser Tyr Thr Phe Val Pro Trp Leu 155 160 165	653
CTC AGC TTT AAA AGG GGA AGT GCC CTA GAA GAA AAA GAG AAT AAA ATA Leu Ser Phe Lys Arg Gly Ser Ala Leu Glu Glu Lys Glu Asn Lys Ile 170 175 180 185	701
TTG GTC AAA GAA ACT GGT TAC TTT TTT ATA TAT GGT CAG GTT TTA TAT Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile Tyr Gly Gln Val Leu Tyr 190 195 200	749
ACT GAT AAG ACC TAC GCC ATG GGA CAT CTA ATT CAG AGG AAG AAG GTC Thr Asp Lys Thr Tyr Ala Met Gly His Leu Ile Gln Arg Lys Lys Val 205 210 215	797
CAT GTC TTT GGG GAT GAA TTG AGT CTG GTG ACT TTG TTT CGA TGT ATT His Val Phe Gly Asp Glu Leu Ser Leu Val Thr Leu Phe Arg Cys Ile 220 225 230	845
CAA AAT ATG CCT GAA ACA CTA CCC AAT AAT TCC TGC TAT TCA GCT GGC Gln Asn Met Pro Glu Thr Leu Pro Asn Asn Ser Cys Tyr Ser Ala Gly 235 240 245	893
ATT GCA AAA CTG GAA GAA GGA GAT GAA CTC CAA CTT GCA ATA CCA AGA Ile Ala Lys Leu Glu Glu Gly Asp Glu Leu Gln Leu Ala Ile Pro Arg 250 255 260 265	941
GAA AAT GCA CAA ATA TCA CTG GAT GGA GAT GTC ACA TTT TTT GGT GCA Glu Asn Ala Gln Ile Ser Leu Asp Gly Asp Val Thr Phe Phe Gly Ala 270 275 280	989
TTG AAA CTG CTG TGACCTACTT ACACCATGTC TGTAGCTATT TTCCTCCCTT Leu Lys Leu Leu 285	1041
TCTCTGTACC TCTAAGAAGA AAGAATCTAA CTGAAAATAC CAAAAAAAAA AAAAAAAAAA	1100

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 285 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

80

Met Asp Asp Ser Thr Glu Arg Glu Gln Ser Arg Leu Thr Ser Cys Leu  
 1 5 10 15  
 Lys Lys Arg Glu Glu Met Lys Leu Lys Glu Cys Val Ser Ile Leu Pro  
 20 25 30  
 Arg Lys Glu Ser Pro Ser Val Arg Ser Ser Lys Asp Gly Lys Leu Leu  
 35 40 45  
 Ala Ala Thr Leu Leu Leu Ala Leu Leu Ser Cys Cys Leu Thr Val Val  
 50 55 60  
 Ser Phe Tyr Gln Val Ala Ala Leu Gln Gly Asp Leu Ala Ser Leu Arg  
 65 70 75 80  
 Ala Glu Leu Gln Gly His His Ala Glu Lys Leu Pro Ala Gly Ala Gly  
 85 90 95  
 Ala Pro Lys Ala Gly Leu Glu Glu Ala Pro Ala Val Thr Ala Gly Leu  
 100 105 110  
 Lys Ile Phe Glu Pro Pro Ala Pro Gly Glu Gly Asn Ser Ser Gln Asn  
 115 120 125  
 Ser Arg Asn Lys Arg Ala Val Gln Gly Pro Glu Glu Thr Val Thr Gln  
 130 135 140  
 Asp Cys Leu Gln Leu Ile Ala Asp Ser Glu Thr Pro Thr Ile Gln Lys  
 145 150 155 160  
 Gly Ser Tyr Thr Phe Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser  
 165 170 175  
 Ala Leu Glu Glu Lys Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr  
 180 185 190  
 Phe Phe Ile Tyr Gly Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met  
 195 200 205  
 Gly His Leu Ile Gln Arg Lys Lys Val His Val Phe Gly Asp Glu Leu  
 210 215 220  
 Ser Leu Val Thr Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu  
 225 230 235 240  
 Pro Asn Asn Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly  
 245 250 255  
 Asp Glu Leu Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu  
 260 265 270  
 Asp Gly Asp Val Thr Phe Phe Gly Ala Leu Lys Leu Leu  
 275 280 285

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 233 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Ser Thr Glu Ser Met Ile Arg Asp Val Glu Leu Ala Glu Glu Ala
1           5           10           15

Leu Pro Lys Lys Thr Gly Gly Pro Gln Gly Ser Arg Arg Cys Leu Phe
          20           25           30

Leu Ser Leu Phe Ser Phe Leu Ile Val Ala Gly Ala Thr Thr Leu Phe
          35           40           45

Cys Leu Leu His Phe Gly Val Ile Gly Pro Gln Arg Glu Glu Ser Pro
          50           55           60

Arg Asp Leu Ser Leu Ile Ser Pro Leu Ala Gln Ala Val Arg Ser Ser
          65           70           75           80

Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
          85           90           95

Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu
          100          105          110

Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser
          115          120          125

Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe Lys Gly Gln Gly
          130          135          140

Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile Ser Arg Ile Ala
          145          150          155          160

Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro
          165          170          175

Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu
          180          185          190

Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu
          195          200          205

```

Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu Asp Phe Ala Glu Ser Gly  
 210 215 220

Gln Val Tyr Phe Gly Ile Ile Ala Leu  
 225 230

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 205 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Thr Pro Pro Glu Arg Leu Phe Leu Pro Arg Val Cys Gly Thr Thr  
 1 5 10 15

Leu His Leu Leu Leu Gly Leu Leu Leu Val Leu Leu Pro Gly Ala  
 20 25 30

Gln Gly Leu Pro Gly Val Gly Leu Thr Pro Ser Ala Ala Gln Thr Ala  
 35 40 45

Arg Gln His Pro Lys Met His Leu Ala His Ser Thr Leu Lys Pro Ala  
 50 55 60

Ala His Leu Ile Gly Asp Pro Ser Lys Gln Asn Ser Leu Leu Trp Arg  
 65 70 75 80

Ala Asn Thr Asp Arg Ala Phe Leu Gln Asp Gly Phe Ser Leu Ser Asn  
 85 90 95

Asn Ser Leu Leu Val Pro Thr Ser Gly Ile Tyr Phe Val Tyr Ser Gln  
 100 105 110

Val Val Phe Ser Gly Lys Ala Tyr Ser Pro Lys Ala Pro Ser Ser Pro  
 115 120 125

Leu Tyr Leu Ala His Glu Val Gln Leu Phe Ser Ser Gln Tyr Pro Phe  
 130 135 140

His Val Pro Leu Leu Ser Ser Gln Lys Met Val Tyr Pro Gly Leu Gln  
 145 150 155 160

Glu Pro Trp Leu His Ser Met Tyr His Gly Ala Ala Phe Gln Leu Thr  
 165 170 175

Gln Gly Asp Gln Leu Ser Thr His Thr Asp Gly Ile Pro His Leu Val  
 180 185 190

Leu Ser Pro Ser Thr Val Phe Phe Gly Ala Phe Ala Leu  
 195 200 205

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 244 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Gly Ala Leu Gly Leu Glu Gly Arg Gly Gly Arg Leu Gln Gly Arg  
 1 5 10 15

Gly Ser Leu Leu Leu Ala Val Ala Gly Ala Thr Ser Leu Val Thr Leu  
 20 25 30

Leu Leu Ala Val Pro Ile Thr Val Leu Ala Val Leu Ala Leu Val Pro  
 35 40 45

Gln Asp Gln Gly Gly Leu Val Thr Glu Thr Ala Asp Pro Gly Ala Gln  
 50 55 60

Ala Gln Gln Gly Leu Gly Phe Gln Lys Leu Pro Glu Glu Glu Pro Glu  
 65 70 75 80

Thr Asp Leu Ser Pro Gly Leu Pro Ala Ala His Leu Ile Gly Ala Pro  
 85 90 95

Leu Lys Gly Gln Gly Leu Gly Trp Glu Thr Thr Lys Glu Gln Ala Phe  
 100 105 110

Leu Thr Ser Gly Thr Gln Phe Ser Asp Ala Glu Gly Leu Ala Leu Pro  
 115 120 125

Gln Asp Gly Leu Tyr Tyr Leu Tyr Cys Leu Val Gly Tyr Arg Gly Arg  
 130 135 140

Ala Pro Pro Gly Gly Gly Asp Pro Gln Gly Arg Ser Val Thr Leu Arg  
 145 150 155 160

Ser Ser Leu Tyr Arg Ala Gly Gly Ala Tyr Gly Pro Gly Thr Pro Glu  
 165 170 175



Leu Leu Leu Glu Gly Ala Glu Thr Val Thr Pro Val Leu Asp Pro Ala  
 180 185 190  
 Arg Arg Gln Gly Tyr Gly Pro Leu Trp Tyr Thr Ser Val Gly Phe Gly  
 195 200 205  
 Gly Leu Val Gln Leu Arg Arg Gly Glu Arg Val Tyr Val Asn Ile Ser  
 210 215 220  
 His Pro Asp Met Val Asp Phe Ala Arg Gly Lys Thr Phe Phe Gly Ala  
 225 230 235 240  
 Val Met Val Gly

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 281 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Gln Gln Pro Phe Asn Tyr Pro Tyr Pro Gln Ile Tyr Trp Val Asp  
 1 5 10 15  
 Ser Ser Ala Ser Ser Pro Trp Ala Pro Pro Gly Thr Val Leu Pro Cys  
 20 25 30  
 Pro Thr Ser Val Pro Arg Arg Pro Gly Gln Arg Arg Pro Pro Pro Pro  
 35 40 45  
 Pro Pro Pro Pro Pro Leu Pro Pro Pro Pro Pro Pro Pro Pro Leu Pro  
 50 55 60  
 Pro Leu Pro Leu Pro Pro Leu Lys Lys Arg Gly Asn His Ser Thr Gly  
 65 70 75 80  
 Leu Cys Leu Leu Val Met Phe Phe Met Val Leu Val Ala Leu Val Gly  
 85 90 95  
 Leu Gly Leu Gly Met Phe Gln Leu Phe His Leu Gln Lys Glu Leu Ala  
 100 105 110  
 Glu Leu Arg Glu Ser Thr Ser Gln Met His Thr Ala Ser Ser Leu Glu  
 115 120 125

85

Lys Gln Ile Gly His Pro Ser Pro Pro Pro Glu Lys Lys Glu Leu Arg  
 130 135 140  
 Lys Val Ala His Leu Thr Gly Lys Ser Asn Ser Arg Ser Met Pro Leu  
 145 150 155 160  
 Glu Trp Glu Asp Thr Tyr Gly Ile Val Leu Leu Ser Gly Val Lys Tyr  
 165 170 175  
 Lys Lys Gly Gly Leu Val Ile Asn Glu Thr Gly Leu Tyr Phe Val Tyr  
 180 185 190  
 Ser Lys Val Tyr Phe Arg Gly Gln Ser Cys Asn Asn Leu Pro Leu Ser  
 195 200 205  
 His Lys Val Tyr Met Arg Asn Ser Lys Tyr Pro Gln Asp Leu Val Met  
 210 215 220  
 Met Glu Gly Lys Met Met Ser Tyr Cys Thr Thr Gly Gln Met Trp Ala  
 225 230 235 240  
 Arg Ser Ser Tyr Leu Gly Ala Val Phe Asn Leu Thr Ser Ala Asp His  
 245 250 255  
 Leu Tyr Val Asn Val Ser Glu Leu Ser Leu Val Asn Phe Glu Glu Ser  
 260 265 270  
 Gln Thr Phe Phe Gly Leu Tyr Lys Leu  
 275 280

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 338 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AGGNTAACTC TCCTGAGGGG TGAGCCAAGC CCTGCCATGT AGTGCACGCA GGACATCANC 60  
 AAACACANNN NNCAGGAAAT AATCCATTCC CTGTGGTCAC TTATTCTAAA GGCCCCAACC 120  
 TTCAAAGTTC AAGTAGTGAT ATGGATGACT CCACAGAAAG GGAGCAGTCA CGCCTTACTT 180  
 CTTGCCTTAA GAAAAGAGAA GAAATGAAAC TGNAAGGAGT GTGTTTCCAT CCTCCCACGG 240  
 AAGGAAAGCC CCTCTNTCCG ATCCTCCAAA GACGGAAAGC TGCTGGCTGC AACCTTGNTG 300

NTGGCATTGT GTTCTTGCTG NCTCAAGGTG GTGTTNTT

338

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 509 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AATTCGGCAN AGNAACTGG TTACTTTTTT ATATATGGTC AGGTTTATA TACTGATAAG	60
ACCTACGCCA TGGGACATCT AGTTCAGAGG AAGAAGGTCC ATGTCTTTGG GGATGAATTG	120
AGTCTGGTGA CTTTGTTCG ATGTATTCAA AATATGCCTG AAACACTACC CAATAATTCC	180
TGCTATTAG CTGGCATTGC AAACTGGNA GGAAGGAGAT GAACTCCAAC TTGCAATACC	240
AGGGGAAAT GCACAATTAT CACTGGGATG GAGATGTTCA CATTTTTGG GTGCCATTGA	300
AACGTCTGTG ACCTNCTTAC ANCANGTGCT GTTNGCTATT TTNCCTNCCT NTTCTNTGGT	360
AACCTCTTAG GAAGGAAGGA TTCTTAACTG GGAAATAACC CAAAAAANN TTAAANGGGT	420
ANGNGNNANA NGNGGGGNG TTNNCNNGNN GNNTTTTNGG NNTATNTTNT NNTNGGGNNN	480
NGTAAAAATG GGGCCNANGG GGGNTTTTT	509

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 497 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AATTCGGCAC GAGCAAGGCC GGCCTGGAGG AAGCTCCAGC TGTCACCGCG GGAAGTAAAA	60
TCTTTGAACC ACCAGCTCCA GGAGAAGGCA ACTCCAGTCA GAACAGCAGA AATAAGCGTG	120
CCGTTTCAGG TCCAGAAGAA ACAGTCACTC AAGACTGCTT GCAACTGNTT GCAGACAGTG	180

AAACACCAAC TATACAAAAA GGCTCCCTTC TGNTGCCACA TTTGGGCCAA GGAATGGAGA 240  
GATTTCCTTCG TCTGGAACA TTTTGCCAAA CTCTTCAGAT ACTCTTNTCT CTCTGGGAAT 300  
CAAAGGAAAA TCTCTACTTA GATTNACACA TTTGTTCCCA TGGGTNTCTT AAGTTTAAA 360  
AGGGGAGTGC CCTTAGGAGG AAAAGGGGAT AAATATTGGC CAAGNACTG GTTANTTTNT 420  
AAATATGGTC AGGTTTNTAT ANCTGGTAGG CCTCGCCATG GGCATTNATT CANGGNGAGG 480  
NCNNTCTTTT GGGNTGA 497

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GTGGGATCCA GCCTCCGGGC AGAGCTG 27

## (2) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GTGAAGCTTT TATTACAGCA GTTCAATGC ACC 33

## (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTGTCATGAG CCTCCGGGCA GAGCTG

26

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTGAAGCTTT TATTACAGCA GTTCAATGC ACC

33

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GTGGGATCCC CGGGCAGAGC TGCAGGGC

28

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GTGGGATCCT TATTACAGCA GTTCAATGC ACC

33

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 129 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GCGGGATCCG CCACCATGAA CTCCTTCTCC ACAAGCGCCT TCGGTCCAGT TGCCTTCTCC	60
CTGGGGCTGC TCCTGGTGTT GCCTGCTGCC TTCCCTGCCC CAGTTGTGAG ACAAGGGGAC	120
CTGGCCAGC	129

## (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GTGGGATCCT TACAGCAGTT TCAATGCACC

30

90

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

5 (a) a nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide having the complete amino acid sequence in Figure 1 (SEQ ID NO:2);

(b) a nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996;

10 (c) a nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide extracellular domain;

(d) a nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide transmembrane domain;

15 (e) a nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide intracellular domain;

(f) a nucleotide sequence encoding a soluble Neutrokin  $\alpha$  polypeptide comprising the extracellular and intracellular domains but lacking the transmembrane domain; and

20 (g) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e) or (f) above.

2. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence in Figure 1 (SEQ ID NO:1).

3. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in Figure 1 (SEQ ID NO:1) encoding the Neutrokin  $\alpha$  polypeptide having the complete amino acid sequence in Figure 1 (SEQ ID NO:2).

4. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding a soluble Neutrokin  $\alpha$  polypeptide comprising the extracellular domain shown in Figure 1 (SEQ ID NO:2).

5. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues n-285 of SEQ ID NO:2, where n is an integer in the range of 2-190

(b) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues 1-m of SEQ ID NO:2, where m is an integer in the range of 274-284;

(c) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues n-m of SEQ ID NO:2, where n and m are integers as defined respectively in (a) and (b) above; and

(d) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Neutrokin  $\alpha$  amino acid sequence encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996 wherein said portion excludes from 1 to 190 amino acids from the amino terminus and from 1 to 11 amino acids from the C-terminus of said complete amino acid sequence.

6. The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone contained in the ATCC Deposit of October 22, 1996.

7. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding the Neutrokin  $\alpha$  polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996.



92

8. The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding a soluble Neutrokin  $\alpha$  polypeptide comprising the extracellular domain encoded by the cDNA clone contained in the ATCC Deposit of October 22, 1996.

9. An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e) or (f) of claim 1 wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.

10. An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a Neutrokin  $\alpha$  polypeptide having an amino acid sequence in (a), (b), (c), (d), (e) or (f) of claim 1.

11. The isolated nucleic acid molecule of claim 10, which encodes an epitope-bearing portion of a Neutrokin  $\alpha$  polypeptide selected from the group consisting of: a polypeptide comprising amino acid residues from about Phe 115 to about Leu 147 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ile 150 to about Tyr 163 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ser 171 to about Phe 194 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Glu 223 to about Tyr 247 (SEQ ID NO:2); and a polypeptide comprising amino acid residues from about Ser 271 to about Phe 278 (SEQ ID NO:2).

12. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.

93

13. A recombinant vector produced by the method of claim 12.

14. A method of making a recombinant host cell comprising  
5 introducing the recombinant vector of claim 13 into a host cell.

15. A recombinant host cell produced by the method of claim 14.

16. A recombinant method for producing a Neutrokin  $\alpha$   
10 polypeptide, comprising culturing the recombinant host cell of claim 15 under  
conditions such that said polypeptide is expressed and recovering said  
polypeptide.

17. An isolated Neutrokin  $\alpha$  polypeptide comprising an amino  
15 acid sequence at least 95% identical to a sequence selected from the group  
consisting of:

(a) the amino acid sequence of the Neutrokin  $\alpha$  polypeptide  
having the complete amino acid sequence in Figure 1 (SEQ ID NO:2);

(b) the amino acid sequence of the Neutrokin  $\alpha$  polypeptide  
20 having the complete amino acid sequence encoded by the cDNA clone  
contained in the the ATCC Deposit of October 22, 1996;

(c) the amino acid sequence of the Neutrokin  $\alpha$  polypeptide  
extracellular domain;

(d) the amino acid sequence of the Neutrokin  $\alpha$  polypeptide  
25 transmembrane domain;

(e) the amino acid sequence of the Neutrokin  $\alpha$  polypeptide  
intracellular domain;

(f) the amino acid sequence of a soluble Neutrokin  $\alpha$  polypeptide  
comprising the domain; and

(g) the amino acid sequence of an epitope-bearing portion of any  
30 one of the polypeptides of (a), (b), (c), (d), (e) or (f).

18. An isolated polypeptide of claim 17 comprising an epitope-bearing portion of the Neutrokin  $\alpha$  protein, wherein said portion is selected from the group consisting of: a polypeptide comprising amino acid residues from about Phe 115 to about Leu 147 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ile 150 to about Tyr 163 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ser 171 to about Phe 194 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Glu 223 to about Tyr 247 (SEQ ID NO:2); a polypeptide comprising amino acid residues from about Ser 271 to about Phe 278 (SEQ ID NO:2).

19. An isolated antibody that binds specifically to a Neutrokin  $\alpha$  polypeptide of claim 17.

20. A pharmaceutical composition comprising a polypeptide of claim 17 and a pharmaceutically acceptable carrier.

21. An isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) the nucleotide sequence of clone HSOAD55R (SEQ ID NO:7);
- (b) the nucleotide sequence of clone HSLAH84R (SEQ ID NO:8);
- (c) the nucleotide sequence of clone HLTBM08R (SEQ ID NO:9);
- (d) the nucleotide sequence of a portion of the sequence shown in Figure 1 (SEQ ID NO:1) wherein said portion comprises at least 30 contiguous nucleotides from nucleotide 1 to nucleotide 809; and
- (e) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c) or (d) above.

1/6

Figure 1

1 AAATTCAGGATAACTCTCCTGAGGGGTGAGCCAAGCCCTGCCATGTAGTGCACGCAGGAC  
61 ATCAACAACACAGATAACAGGAAATGATCCATTCCCTGTGGTCACTTATTCTAAAGGCC  
121 CCAACCTTCAAAGTTCAAGTAGTGATATGGATGACTCCACAGAAAGGAGCAGTCACGCC  
1 M D D S T E R E Q S R L  
181 TTACTTCTTGCCCTTAAGAAAAGAGAAGAAATGAACTGAAGGAGTGTGTTTCCATCCTCC  
13 T S C L K K R E E M K L K E C V S I L P  
241 CAAGGAAGGAAGCCCTCTGTCCGATCCTCCAAGACGGAAGCTGCTGGCTGCAACCT  
33 R K E S P S V R S S K D G K L L A A T L  
301 TGCTGCTGGCACTGCTGTCTGTCTGCTGCTCACGGTGGTGTCTTCTTACCAGGTGGCCGCC  
53 L L A L L S C C L T V V S F Y O V A A L  
361 TGCAAGGGGACCTGGCCAGCCTCCGGGCAGAGCTGCAGGGCCACCACGGGAGAAGCTGC  
73 Q G D L A S L R A E L Q G H H A E K L P  
421 CAGCAGGAGCAGGAGCCCCAAGGCCGGCCTGGAGGAAGCTCCAGCTGTACCGCGGGAC  
93 A G A G A P K A G L E E A P A V T A G L  
481 TGAAATCTTTGAACCAACAGCTCCAGGAGAAGGCAACTCCAGTCAGAACAGCAGAAATA  
113 K I F E P P A P G E G N S S Q N S R N K  
541 AGCGTGCCGTTTCAGGGTCCAGAAGAAACAGTCACTCAAGACTGCTTGCAACTGATTGCAG  
133 R A V Q G P E E T V T Q D C L Q L I A D  
601 ACAGTGAACACCAACTATACAAAAGGATCTTACACATTTGTTCCATGGCTTCTCAGCT  
153 S E T P T I Q K G S Y T F V P W L L S F  
661 TTAAGAGGGGAAGTGCCCTAGAAGAAAAGAGAATAAAATATTGGTCAAAGAACTGGTT  
173 K R G S A L E E K E N K I L V K E T G Y  
721 ACTTTTTATATATGGTCAGGTTTATATACTGATAAGACCTACGCCATGGGACATCTAA  
193 F F I Y G Q V L Y T D K T Y A M G H L I  
781 TTCAGAGGAAGAAGTCCATGTCTTTGGGGATGAATTGAGTCTGGTGACTTTGTTTCGAT  
213 Q R K K V H V F G D E L S L V T L F R C  
841 GTATTCAAATATGCCTGAAACACTACCCAATAATTCTGCTATTTCAGCTGGCATTGCAA  
233 I Q N M P E T L P N N S C Y S A G I A K  
901 AACTGGAAGAAGGAGATGAACTCCAATTGCAATACCAAGAGAAATGCACAAATATCAC  
253 L E E G D E L Q L A I P R E N A Q I S L  
961 TGGATGGAGATGTCACATTTTGGTGCAATTGAACTGCTGTGACCTACTTACACCATGT  
273 D G D V T F F G A L K L L  
1021 CTGTAGCTATTTTCTCTCCCTTCTCTGTACCTCTAAGAAGAAAGAACTTAAGTAAATA  
1081 CCAAAAAAAAAAAAAAAAAA

2/6


Figure 2

1	M	S	T	E	S	M	I	-	-	-	-	-	-	-	-	-	-	-	-	-	R	D	V	E	L	TNFalpha										
1	M	T	P	P	E	R	L	F	L	P	R	V	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFbeta									
1	M	G	A	L	G	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	E	G	R	G	G	R	L	LTbeta								
1	M	Q	Q	P	F	N	Y	P	Y	P	Q	I	Y	W	V	D	S	S	A	S	S	P	W	A	P	P	G	T	V	L	FASL					
1	M	D	D	S	T	E	R	E	Q	S	R	L	-	-	-	-	-	-	-	-	T	S	C	L	K	K	R	E	E	M	K	L	Neutrokin alpha			
13	-	A	-	E	E	A	L	P	K	K	T	G	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFalpha			
13	-	-	C	G	T	T	L	H	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFbeta			
14	-	Q	G	R	G	S	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	L	A	V	A	G	-	-	LTbeta			
31	-	P	C	P	T	S	V	P	R	R	P	G	Q	R	R	P	P	P	P	P	P	P	P	P	P	L	P	P	P	P	P	P	FASL			
25	K	E	C	V	S	I	L	P	R	K	-	-	E	S	P	S	V	R	S	S	K	D	G	K	L	L	A	A	T	L	-	-	-	Neutrokin alpha		
23	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	G	P	Q	G	S	R	R	C	L	F	L	S	L	TNFalpha		
19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	L	G	L	L	L	V	L	-	TNFbeta			
26	A	T	S	L	V	T	-	-	L	L	L	A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	V	P	I	T	V	-	-	LTbeta		
60	P	P	P	L	P	P	-	-	L	P	L	P	P	L	K	K	R	G	N	H	S	T	G	L	C	L	L	V	M	F	-	-	-	FASL		
53	L	L	A	L	L	S	C	C	L	T	V	V	S	F	Y	Q	V	A	A	L	Q	G	D	L	A	S	I	R	A	E	-	-	-	Neutrokin alpha		
36	F	S	F	L	-	-	I	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFalpha		
29	L	P	G	A	Q	G	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFbeta		
41	I	A	V	L	A	L	V	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	LTbeta		
88	F	M	V	L	V	A	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	FASL		
83	L	Q	G	H	H	A	E	K	L	P	A	G	A	G	A	P	K	A	G	L	E	E	A	P	A	V	T	A	G	L	-	-	-	-	Neutrokin alpha	
61	E	-	-	E	S	P	R	D	L	S	L	I	S	P	L	A	Q	A	V	R	S	S	S	R	T	P	S	D	-	-	-	-	-	-	TNFalpha	
41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFbeta		
59	A	-	-	D	P	G	A	Q	A	Q	Q	G	L	G	F	O	K	L	P	E	E	E	P	E	T	D	L	S	P	G	-	-	-	-	LTbeta	
115	R	-	-	E	S	T	S	O	M	H	T	A	S	S	L	E	K	Q	I	G	H	P	S	P	P	P	E	K	K	E	-	-	-	-	FASL	
113	K	I	F	E	P	P	A	P	G	E	G	N	S	S	Q	N	S	R	N	K	R	A	V	Q	G	P	E	T	V	-	-	-	-	-	Neutrokin alpha	
87	-	K	P	V	A	H	V	V	A	N	P	Q	A	E	G	-	-	-	-	-	-	-	-	-	-	L	Q	V	I	N	R	R	-	-	TNFalpha	
61	L	K	P	A	A	H	L	I	G	D	P	S	K	Q	N	-	-	-	-	-	-	-	-	-	-	L	L	W	R	A	N	T	-	-	TNFbeta	
87	L	-	P	A	A	H	L	T	G	A	P	L	K	-	G	Q	G	-	-	-	-	-	-	-	-	L	G	W	E	T	T	K	-	-	LTbeta	
143	L	R	K	V	A	H	L	T	G	K	S	N	S	R	S	M	P	-	-	-	-	-	-	-	-	L	E	W	E	D	T	Y	-	-	FASL	
143	T	Q	D	C	L	Q	L	I	A	D	S	E	T	P	T	I	Q	K	G	S	Y	T	F	V	P	N	L	-	-	-	-	-	-	-	Neutrokin alpha	
109	A	N	A	L	L	A	N	G	V	E	L	R	D	N	-	Q	L	V	V	P	S	E	G	L	Y	L	I	Y	S	Q	-	-	-	-	-	TNFalpha
84	D	R	A	E	L	Q	D	C	F	S	L	S	N	N	-	S	L	L	V	P	T	S	G	I	Y	F	V	Y	S	Q	-	-	-	-	-	TNFbeta
109	E	Q	A	F	L	T	S	G	T	Q	F	S	D	A	E	G	L	A	L	P	Q	D	G	L	Y	Y	L	Y	C	L	-	-	-	-	-	LTbeta
167	G	I	V	L	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	FASL	
170	-	L	S	F	K	R	G	S	A	L	E	E	K	E	N	K	I	L	V	K	E	T	G	Y	F	F	I	Y	G	Q	-	-	-	-	-	Neutrokin alpha
138	V	L	F	K	G	Q	G	C	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFalpha	
113	V	V	F	S	G	K	A	Y	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFbeta	
139	V	G	Y	R	G	R	A	P	P	G	G	D	P	Q	G	R	S	V	T	L	R	S	S	L	Y	R	A	G	G	-	-	-	-	-	LTbeta	
195	V	Y	F	R	G	S	C	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	FASL	
199	V	L	Y	T	D	K	T	Y	A	M	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Neutrokin alpha	
162	S	Y	O	T	K	V	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFalpha	
141	Q	Y	P	F	H	V	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFbeta	
169	A	Y	G	P	G	T	P	E	L	L	L	E	G	A	E	T	V	T	P	V	L	D	P	A	R	R	Q	G	Y	G	-	-	-	-	-	LTbeta
217	K	Y	P	Q	D	L	V	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	FASL	
223	E	L	S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Neutrokin alpha	
188	K	P	W	Y	E	P	I	Y	L	G	G	V	F	Q	L	E	K	G	D	R	L	S	A	E	I	N	R	P	D	Y	-	-	-	-	-	TNFalpha
161	E	P	W	L	H	S	M	Y	H	G	A	A	F	Q	L	T	Q	G	D	O	I	S	T	H	T	D	G	I	P	H	-	-	-	-	-	TNFbeta
199	P	L	W	Y	T	S	V	G	F	G	G	L	V	Q	L	R	R	G	E	R	V	Y	V	N	I	S	H	P	D	M	-	-	-	-	-	LTbeta
237	Q	M	W	A	R	S	S	Y	L	G	A	V	F	N	L	T	S	A	D	H	L	Y	V	N	V	S	E	L	S	L	-	-	-	-	-	FASL
243	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Neutrokin alpha	
218	L	D	F	A	E	S	G	Q	V	Y	F	G	I	I	A	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFalpha
191	L	V	L	S	P	S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TNFbeta
229	V	D	F	A	R	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	LTbeta
267	V	N	F	E	E	S	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	FASL
269	Q	I	S	L	D	G	D	V	T	F	F	G	A	L	K	L	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Neutrokin alpha

Decoration 'Decoration #1': Shade (with solid black) residues that match the Consensus exactly.

3/6

Figure 3



4/6

FIGURE 4 A

	1					50
HSOAD55R	.....A	GGNTAACTCT	CCTGAGGGGT	GAGCCAAGCC	CTGCCATGTA	
HNEDU15X	...AAATTCA	GGATAACTCT	CCTGAGGGGT	GAGCCAAGCC	CTGCCATGTA	
HSLAH84R	.AATTCGGCA	NAGNAACTG	GTTACTTTTT	TATATATGGT	CAGGTTTTAT	
HLTBM08R	AATTCGGCAC	GAGCAAGGCC	GGCCTGGAGG	AAGCTCCAGC	TGTCACCGCG	
	51					100
HSOAD55R	GTGCACGCAG	GACATCANCA	A..ACACANN	NNNCAGGAAA	TAATCCATTTC	
HNEDU15X	GTGCACGCAG	GACATCAACA	A..ACACAGA	TAACAGGAAA	TGATCCATTTC	
HSLAH84R	ATACTGATAA	GACCTACGCC	ATGGGACATC	TAGTTCAGAG	GAAGAAGGTC	
HLTBM08R	GGACTGAAAA	TCTTTGAACC	ACCAGCTCCA	GGAGAAGGCA	ACTCCAGTCA	
	101					150
HSOAD55R	CCTGTGGTCA	CTTATTCTAA	AGGCCCAAC	CTTCAAAGTT	CAAGTAGTGA	
HNEDU15X	CCTGTGGTCA	CTTATTCTAA	AGGCCCAAC	CTTCAAAGTT	CAAGTAGTGA	
HSLAH84R	CATGTCTTTG	GGGATGAATT	GAGTCTGGTG	ACTTTGTTTC	GATGTATTCA	
HLTBM08R	GAACAGCAGA	AATAAGCGTG	CCGTTCAGGG	TCCAGAAGAA	ACAGTCACTC	
	151					200
HSOAD55R	TATGGATGAC	TCCACAGAAA	GGGAGCAGTC	ACGCCTTACT	TCTTGCCTTA	
HNEDU15X	TATGGATGAC	TCCACAGAAA	GGGAGCAGTC	ACGCCTTACT	TCTTGCCTTA	
HSLAH84R	AAATATGCCT	GAAACACTAC	CCAATAATTC	CTGCTATTCA	GCTGGCATTG	
HLTBM08R	AAGACTGCTT	GCAACTGNNT	GCAGACAGTG	AAACACCAAC	TATACAAAAA	
	201					250
HSOAD55R	AGAAAAGAGA	AGAAATGAAA	CTGNAAGGAG	TGTGTTTCCA	TCCTCCCACG	
HNEDU15X	AGAAAAGAGA	AGAAATGAAA	CT.GAAGGAG	TGTGTTTCCA	TCCTCCCACG	
HSLAH84R	CAAACTGGN	AGGAAGGA..	...GATGAAC	TCCAACTTGC	AATACCAGGG	
HLTBM08R	GGCTCCCTTC	TGNTGCCACA	TTTGGGCCAA	GGAATGGAGA	GATTTCTTTC	
	251					300
HSOAD55R	GAAGGAAAGC	CCCTCTNTCC	GATCCTCCAA	AGACGGAAAG	CTGCTGGCTG	
HNEDU15X	GAAGGAAAGC	CCCTCTGTCC	GATCCTCCAA	AGACGGAAAG	CTGCTGGCTG	
HSLAH84R	GAAAATGCAC	AATTATCACT	GGGATGGAGA	TGTTTCACATT	TTTTGGGTGC	
HLTBM08R	TCTGGAAACA	TTTTGCCAAA	CTCTTCAGAT	ACTCTTTNCT	CTCTGGGAAT	
	301					350
HSOAD55R	CAACCTTGNT	GNTGGCATTG	TGTTCTTGCT	GNCTCAAGGT	GGTGTNTTT.	
HNEDU15X	CAACCTTGCT	GCTGGCACTG	CTGTCTTGCT	GCCTCACGGT	GGTGTCTTTC	
HSLAH84R	CATTGAAACT	GCTGTGACCT	NCTTACANCA	NGTGTGTN	GCTATTTTNC	
HLTBM08R	CAAAGGAAAA	TCTCTACTTA	GATTNACACA	TTTGTTCCTA	TGGGTNTCTT	
	351					400
HSOAD55R	.....	.....	.....	.....	.....	
HNEDU15X	TACCAGGTGG	CCGCCCTGCA	AGGGGACCTG	GCCAGCCTCC	GGGCAGAGCT	
HSLAH84R	CTNCCTNTTC	TNTGGTAACC	TCTTAGGAAG	GAAGGATTCT	TAAGTGGGAA	
HLTBM08R	AAGTTTAAA	AGGGGAGTGC	CCTTAGGAGG	AAAAGGGGAT	AAATATTGGC	

5/6

FIGURE 4 B

	401				450
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	GCAGGGCCAC	CACGCGGAGA	AGCTGCCAGC	AGGAGCAGGA	GCCCCCAAGG
HSLAH84R	ATAACCCAAA	AAAANNTTAA	ANGGGTANGN	GNNANANGNG	GGGNNGTTNN
HLTBM08R	CAAGGNACTG	GTTANTTTNT	AAATATGGTC	AGGTTTNTAT	ANCTGGTAGG
	451				500
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	CCGGCCTGGA	GGAAGCTCCA	GCTGTCACCG	CGGGACTGAA	AATCTTTGAA
HSLAH84R	CNNGNNGNNT	TTTNGGNNTA	TNTNTNTNTN	GGGNNNNGTA	AAAATGGGGC
HLTBM08R	CCTCGCCATG	GGCATTNATT	CANGGNGAGG	NCNNTCTTTT	GGGNTGA...
	501				550
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	CCACCAGCTC	CAGGAGAAGG	CAACTCCAGT	CAGAACAGCA	GAAATAAGCG
HSLAH84R	CNANGGGGGN	TTTTT.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	551				600
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	TGCCGTTTTCAG	GGTCCAGAAG	AAACAGTCAC	TCAAGACTGC	TTGCAACTGA
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	601				650
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	TTGCAGACAG	TGAAACACCA	ACTATACAAA	AAGGATCTTA	CACATTTGTT
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	651				700
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	CCATGGCTTC	TCAGCTTTAA	AAGGGGAAGT	GCCCTAGAAG	AAAAAGAGAA
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	701				750
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	TAAAATATTG	GTCAAAGAAA	CTGGTTACTT	TTTTATATAT	GGTCAGGTTT
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	751				800
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	TATATACTGA	TAAGACCTAC	GCCATGGGAC	ATCTAATTCA	GAGGAAGAAG
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....



6/6

FIGURE 4 C

	801				850
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	GTCCATGTCT	TTGGGGATGA	ATTGAGTCTG	GTGACTTTGT	TTCGATGTAT
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	851				900
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	TCAAAATATG	CCTGAAACAC	TACCCAATAA	TTCTTGCTAT	TCAGCTGGCA
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	901				950
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	TTGCAAACT	GGAAGAAGGA	GATGAACTCC	AACTTGCAAT	ACCAAGAGAA
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	951				1000
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	AATGCACAAA	TATCACTGGA	TGGAGATGTC	ACATTTTTTG	GTGCATTGAA
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	1001				1050
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	ACTGCTGTGA	CCTACTTACA	CCATGTCTGT	AGCTATTTTC	CTCCCTTTCT
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	1051				1100
HSOAD55R	.....	.....	.....	.....	.....
HNEDU15X	CTGTACCTCT	AAGAAGAAAG	AATCTAACTG	AAAATACCAA	AAAAAAAAAA
HSLAH84R	.....	.....	.....	.....	.....
HLTBM08R	.....	.....	.....	.....	.....
	1101				
HSOAD55R	.....				
HNEDU15X	AAAAAA				
HSLAH84R	.....				
HLTBM08R	.....				

PCT / U S 9 6 / 1 7 9 5 7

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

<p>A. The indications made below relate to the microorganism referred to in the description on page <u>8</u>, line <u>1</u></p>	
<p><b>B. IDENTIFICATION OF DEPOSIT</b> <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span></p>	
<p>Name of depositary institution <b>American Type Culture Collection</b></p>	
<p>Address of depositary institution (including postal code and country) <b>12301 Parklawn Drive Rockville, Maryland 20852 United States of America</b></p>	
<p>Date of deposit <b>22 October 1996</b></p>	<p>Accession Number <b>ATTC Designation 97768</b></p>
<p><b>C. ADDITIONAL INDICATIONS</b> (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input checked="" type="checkbox"/></span></p>	
<p><b>DNA Plasmid, HNEDU15B</b> In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).</p>	
<p><b>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE</b> (if the indications are not for all designated States)</p>    	
<p><b>E. SEPARATE FURNISHING OF INDICATIONS</b> (leave blank if not applicable)</p> <p>The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")</p>    	

<p style="text-align: center;">For receiving Office use only</p> <p><input type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer</p>	<p style="text-align: center;">For International Bureau use only</p> <p><input type="checkbox"/> This sheet was received by the International Bureau on:</p> <p>Authorized officer</p>
---	--

page 2

**DENMARK**

The applicant hereby request that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent office or any person approved by the applicant in the individual case.

**SWEDEN**

The applicant hereby request that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent office or any person approved by the applicant in the individual case.

**UNITED KINGDOM**

The applicant hereby request that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for international publication of the application.

**NETHERLANDS**

The applicant hereby request that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in Rule 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**SINGAPORE**

The applicant hereby request that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for international publication of the application.

**NORWAY**

The applicant hereby request that, until the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Norwegian Patent office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Registration), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ICELAND**

The applicant hereby request that, until the application has been laid open to public inspection (by the Icelandic Patent Office), or has been finally decided upon by the Icelandic Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 96/17957

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C07K14/52 C12N1/21 C12N5/10 C07K16/24  
A61K38/19

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

No relevant documents disclosed  
-----

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*G\* document member of the same patent family

Date of the actual completion of the international search

23 July 1997

Date of mailing of the international search report

28.07.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Espen, J

THIS PAGE BLANK (USPTO)